Cytokinetics Inc
Buy, Hold or Sell?

Let's analyse Cytokinetics together

Penke I guess you are interested in Cytokinetics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cytokinetics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cytokinetics Inc

I send you an email if I find something interesting about Cytokinetics Inc.

Quick analysis of Cytokinetics (30 sec.)

What can you expect buying and holding a share of Cytokinetics? (30 sec.)

How much money do you get?

$0.03

When do you have the money?

1 year

How often do you get paid?

2.5%

What is your share worth?

Current worth

$-3.69

Expected worth in 1 year

$-6.36

How sure are you?

27.5%

+ What do you gain per year?

Total Gains per Share

$-2.63

Return On Investment

-4.1%

For what price can you sell your share?

Current Price per Share

$64.80

Expected price per share

$54.74 - $80.99

How sure are you?

50%

1. Valuation of Cytokinetics (5 min.)

Live pricePrice per Share (EOD)

$64.80

Book Value per Share

$-3.69

Intrinsic Value Per Share

$-75.33 - $-20.01

Total Value Per Share

$-79.02 - $-23.70

My calculation of the intrinsic value of Cytokinetics is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.29) 3Y: ($-0.73) TTM: ($-0.99)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($-0.01) 3Y: ($-0.10) TTM: ($0.07)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-3.74	$-1.30	$-4.45 - $-1.41
2	$-8.65	$-2.78	$-5.98 - $-1.64
3	$-14.59	$-4.43	$-7.50 - $-1.88
4	$-21.43	$-6.25	$-9.03 - $-2.11
5	$-29.06	$-8.22	$-10.56 - $-2.35
6	$-37.35	$-10.33	$-12.08 - $-2.58
7	$-46.21	$-12.58	$-13.61 - $-2.82
8	$-55.54	$-14.94	$-15.14 - $-3.05
9	$-65.27	$-17.42	$-16.66 - $-3.29
10	$-75.33	$-20.01	$-18.19 - $-3.52

2. Growth of Cytokinetics (5 min.)

Is Cytokinetics growing?

	Current year	Previous year	Grow	Grow %
How rich?	-$386.3m	$25.9m	-$372.7m	-107.5%

How much money is Cytokinetics making?

	Current year	Previous year	Grow	Grow %
Making money	-$131m	-$109.3m	-$21.7m	-16.6%
Net Profit Margin	-15,017.3%	-5,638.9%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Cytokinetics (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#1005 / 1010

Most Revenue
#448 / 1010

Most Profit
#986 / 1010

Most Efficient
#952 / 1010

What can you expect buying and holding a share of Cytokinetics? (5 min.)

Welcome investor! Cytokinetics's management wants to use your money to grow the business. In return you get a share of Cytokinetics.

What can you expect buying and holding a share of Cytokinetics?

First you should know what it really means to hold a share of Cytokinetics. And how you can make/lose money.

Speculation

The Price per Share of Cytokinetics is $64.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Cytokinetics.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cytokinetics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-3.69. Based on the TTM, the Book Value Change Per Share is $-0.67 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.84 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.01 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Cytokinetics.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-1.31	-2.0%	-1.26	-1.9%	-0.93	-1.4%	-0.66	-1.0%	-0.39	-0.6%
Usd Book Value Change Per Share	0.50	0.8%	-0.67	-1.0%	-0.84	-1.3%	-0.20	-0.3%	-0.11	-0.2%
Usd Dividend Per Share	0.00	0.0%	0.01	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	0.50	0.8%	-0.66	-1.0%	-0.84	-1.3%	-0.20	-0.3%	-0.10	-0.2%
Usd Price Per Share	83.49	-	45.19	-	42.59	-	29.73	-	19.21	-
Price to Earnings Ratio	-15.94	-	-8.88	-	-20.05	-	-21.87	-	-15.37	-
Price-to-Total Gains Ratio	166.38	-	18.29	-	-242.44	-	-109.76	-	-15.71	-
Price to Book Ratio	-22.60	-	-13.98	-	-72.89	-	-16.33	-	-2.21	-
Price-to-Total Gains Ratio	166.38	-	18.29	-	-242.44	-	-109.76	-	-15.71	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	64.8
Number of shares	15

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.01	0.00
Usd Book Value Change Per Share	-0.67	-0.20
Usd Total Gains Per Share	-0.66	-0.20
Gains per Quarter (15 shares)	-9.86	-2.93
Gains per Year (15 shares)	-39.43	-11.72

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	1	-40	-49	0	-12	-22
2	1	-80	-88	0	-24	-34
3	2	-120	-127	0	-35	-46
4	2	-160	-166	0	-47	-58
5	3	-200	-205	1	-59	-70
6	3	-240	-244	1	-71	-82
7	4	-280	-283	1	-83	-94
8	4	-319	-322	1	-95	-106
9	5	-359	-361	1	-106	-118
10	5	-399	-400	1	-118	-130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	0.0	4.0	0.0	0.0%	0.0	12.0	0.0	0.0%	0.0	20.0	0.0	0.0%	3.0	37.0	0.0	7.5%	6.0	75.0	1.0	7.3%
Book Value Change Per Share	1.0	3.0	0.0	25.0%	2.0	10.0	0.0	16.7%	4.0	16.0	0.0	20.0%	11.0	29.0	0.0	27.5%	20.0	62.0	0.0	24.4%
Dividend per Share	1.0	0.0	3.0	25.0%	1.0	0.0	11.0	8.3%	1.0	0.0	19.0	5.0%	1.0	0.0	39.0	2.5%	2.0	0.0	80.0	2.4%
Total Gains per Share	1.0	3.0	0.0	25.0%	2.0	10.0	0.0	16.7%	4.0	16.0	0.0	20.0%	11.0	29.0	0.0	27.5%	20.0	62.0	0.0	24.4%

Fundamentals of Cytokinetics

About Cytokinetics Inc

https://www.cytokinetics.com
Biotechnology
423
350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Google Maps Bing Maps

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 05:44:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cytokinetics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Cytokinetics earns for each $1 of revenue.

Above 10% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
A Net Profit Margin of -8,187.6% means that $-81.88 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cytokinetics Inc:

The MRQ is -8,187.6%. The company is making a huge loss. -2
The TTM is -15,017.3%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-8,187.6%	TTM	-15,017.3%	+6,829.7%
TTM	-15,017.3%	YOY	-5,638.9%	-9,378.4%
TTM	-15,017.3%	5Y	-4,583.2%	-10,434.1%
5Y	-4,583.2%	10Y	3,214.0%	-7,797.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-8,187.6%	-207.2%	-7,980.4%
TTM	-15,017.3%	-216.8%	-14,800.5%
YOY	-5,638.9%	-282.3%	-5,356.6%
5Y	-4,583.2%	-436.8%	-4,146.4%
10Y	3,214.0%	-597.3%	+3,811.3%

Measures how much net profit Cytokinetics earns for each $1 of revenue.

Revenue is the amount of profit Cytokinetics generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Cytokinetics earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Cytokinetics makes more profit. This shows the investor how efficiently Cytokinetics is operating in general and compared to other companies in the same industry. Cytokinetics operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Cytokinetics. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Cytokinetics is -81.88. This means that Cytokinetics earned $-81.88 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -207.2%.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Cytokinetics with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Cytokinetics sells assets (profit will increase while costs remain the same).
It won’t show what part of Cytokinetics is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Cytokinetics

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Cytokinetics = -136,896
Total revenue MRQ Cytokinetics = 1,672
$-136,896 / $1,672 = -81.88 or -8,187.6%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Cytokinetics is using its assets to generate profit.

Above 5% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
-16.6% Return on Assets means that Cytokinetics generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cytokinetics Inc:

The MRQ is -16.6%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -16.3%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-16.6%	TTM	-16.3%	-0.3%
TTM	-16.3%	YOY	-11.2%	-5.1%
TTM	-16.3%	5Y	-12.1%	-4.2%
5Y	-12.1%	10Y	-9.4%	-2.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-16.6%	-13.3%	-3.3%
TTM	-16.3%	-12.8%	-3.5%
YOY	-11.2%	-11.6%	+0.4%
5Y	-12.1%	-13.8%	+1.7%
10Y	-9.4%	-15.6%	+6.2%

Shows how efficient Cytokinetics is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Cytokinetics is using its resources to generate profit. If the return on assets (-16.6%) from Cytokinetics are higher than the Biotechnology mean (-13.3%) that means Cytokinetics is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Cytokinetics is -16.6%. This means the company generated $-0.17 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Cytokinetics

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Cytokinetics = -136,896
Total assets MRQ (balance sheet) from Cytokinetics = 824,316
-136,896 / 824,316 = -0.17 or -16.6%

ROA is an important ratio as it will tell you how effectively Cytokinetics is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Cytokinetics is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
0.0% Return on Equity means Cytokinetics generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cytokinetics Inc:

The MRQ is 0.0%. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.0%
TTM	-	YOY	-28.2%	+28.2%
TTM	-	5Y	-75.5%	+75.5%
5Y	-75.5%	10Y	-47.4%	-28.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	-16.9%	+16.9%
TTM	-	-16.1%	+16.1%
YOY	-28.2%	-14.9%	-13.3%
5Y	-75.5%	-19.3%	-56.2%
10Y	-47.4%	-20.1%	-27.3%

Shows how efficient Cytokinetics is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Cytokinetics is 0.0%. This means Cytokinetics generated $0.00 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if Cytokinetics existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Cytokinetics

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Cytokinetics = -136,896
Shareholders equity (balance sheet) MRQ Cytokinetics = -386,323
-136,896 / -386,323 = 0.00 or 0.0%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Cytokinetics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Cytokinetics is operating .

Measures how much profit Cytokinetics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
An Operating Margin of -7,620.7% means the company generated $-76.21 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cytokinetics Inc:

The MRQ is -7,620.7%. The company is operating very inefficient. -2
The TTM is -14,185.4%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-7,620.7%	TTM	-14,185.4%	+6,564.7%
TTM	-14,185.4%	YOY	-4,399.3%	-9,786.1%
TTM	-14,185.4%	5Y	-4,089.8%	-10,095.5%
5Y	-4,089.8%	10Y	2,900.6%	-6,990.4%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-7,620.7%	-298.0%	-7,322.7%
TTM	-14,185.4%	-238.5%	-13,946.9%
YOY	-4,399.3%	-288.4%	-4,110.9%
5Y	-4,089.8%	-486.2%	-3,603.6%
10Y	2,900.6%	-628.4%	+3,529.0%

Measures how efficient Cytokinetics is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Cytokinetics is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Cytokinetics is -7,620.7%. This means that Cytokinetics earned $-76.21 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -298.0%.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Cytokinetics

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Cytokinetics = -127,418
Total revenue MRQ Cytokinetics = 1,672
$-127,418 / $1,672 = -76.21 or -7,620.7%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Cytokinetics is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 77.21 means that the operating costs are $77.21 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cytokinetics Inc:

The MRQ is 77.207. The company is inefficient in keeping operating costs low. -1
The TTM is 142.854. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	77.207	TTM	142.854	-65.647
TTM	142.854	YOY	44.993	+97.861
TTM	142.854	5Y	41.968	+100.886
5Y	41.968	10Y	-28.203	+70.171

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	77.207	3.235	+73.972
TTM	142.854	3.310	+139.544
YOY	44.993	3.838	+41.155
5Y	41.968	5.679	+36.289
10Y	-28.203	7.823	-36.026

Measures how efficient Cytokinetics is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Cytokinetics is 7,720.7%. This means that Cytokinetics earned $77.21 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.24.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Cytokinetics

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(6,335 +122,755) \ 1,672 = 77.21

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Cytokinetics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Cytokinetics is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 6.12 means the company has $6.12 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cytokinetics Inc:

The MRQ is 6.117. The company is very able to pay all its short-term debts. +2
The TTM is 7.832. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	6.117	TTM	7.832	-1.715
TTM	7.832	YOY	9.824	-1.992
TTM	7.832	5Y	9.288	-1.456
5Y	9.288	10Y	7.684	+1.605

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	6.117	3.863	+2.254
TTM	7.832	4.169	+3.663
YOY	9.824	5.337	+4.487
5Y	9.288	6.122	+3.166
10Y	7.684	6.434	+1.250

Measures if Cytokinetics is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Cytokinetics if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Cytokinetics is 6.12. This means Cytokinetics has $6.12 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.86.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Cytokinetics

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
628,051 \ 102,678) = 6.12

The current ratio measures if Cytokinetics is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Cytokinetics is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Cytokinetics does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Cytokinetics is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Cytokinetics is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
A Quick Ratio of 10.89 means the company can pay off $10.89 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cytokinetics Inc:

The MRQ is 10.891. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 14.011. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	10.891	TTM	14.011	-3.120
TTM	14.011	YOY	17.949	-3.938
TTM	14.011	5Y	16.303	-2.292
5Y	16.303	10Y	13.144	+3.160

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	10.891	3.504	+7.387
TTM	14.011	3.991	+10.020
YOY	17.949	5.371	+12.578
5Y	16.303	6.088	+10.215
10Y	13.144	6.395	+6.749

Measures if Cytokinetics is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Cytokinetics can pay off its short term debts. This shows if Cytokinetics can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Cytokinetics is 10.89. This means that Cytokinetics can pay off $10.89 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.50.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Cytokinetics

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Cytokinetics: (615,199 + 501,800 +1,283) / 102,678 = 10.89

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Cytokinetics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Cytokinetics assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Cytokinetics to Biotechnology industry mean.
A Debt to Asset Ratio of 1.47 means that Cytokinetics assets are financed with 146.9% credit (debt) and the remaining percentage (100% - 146.9%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Cytokinetics Inc:

The MRQ is 1.469. The company is unable to pay all its debts by selling its assets. -2
The TTM is 1.436. The company is unable to pay all its debts by selling its assets. -2

Trends

Current period		Compared to		+/-
MRQ	1.469	TTM	1.436	+0.032
TTM	1.436	YOY	0.960	+0.476
TTM	1.436	5Y	1.049	+0.387
5Y	1.049	10Y	0.762	+0.288

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.469	0.339	+1.130
TTM	1.436	0.337	+1.099
YOY	0.960	0.271	+0.689
5Y	1.049	0.368	+0.681
10Y	0.762	0.388	+0.374

Measures how much % of Cytokinetics assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Cytokinetics than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Cytokinetics to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Cytokinetics is 1.47. This means means that Cytokinetics is financed with 146.9% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 386.3%.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Cytokinetics has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Cytokinetics

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
1,210,639 \ 824,316 = 146.9% or 1.47.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Cytokinetics is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Cytokinetics to the Biotechnology industry mean.
A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cytokinetics Inc:

The MRQ is 0.000. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.000
TTM	-	YOY	3.073	-3.073
TTM	-	5Y	6.079	-6.079
5Y	6.079	10Y	3.724	+2.355

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	0.392	-0.392
TTM	-	0.403	-0.403
YOY	3.073	0.335	+2.738
5Y	6.079	0.427	+5.652
10Y	3.724	0.461	+3.263

Measures if Cytokinetics is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Cytokinetics is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Cytokinetics is 0.00. This means that Cytokinetics can pay off $0.00 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Cytokinetics

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
1,210,639 \ -386,323 = 0.00 or 0.0%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Cytokinetics Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cytokinetics generates.

Above 15 is considered overpriced but always compare Cytokinetics to the Biotechnology industry mean.
A PE ratio of -15.94 means the investor is paying $-15.94 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cytokinetics Inc:

The EOD is -12.375. Based on the earnings, the company is expensive. -2
The MRQ is -15.945. Based on the earnings, the company is expensive. -2
The TTM is -8.883. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-12.375	MRQ	-15.945	+3.569
MRQ	-15.945	TTM	-8.883	-7.061
TTM	-8.883	YOY	-20.052	+11.168
TTM	-8.883	5Y	-21.868	+12.985
5Y	-21.868	10Y	-15.370	-6.498

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-12.375	-2.300	-10.075
MRQ	-15.945	-2.656	-13.289
TTM	-8.883	-2.718	-6.165
YOY	-20.052	-4.145	-15.907
5Y	-21.868	-6.258	-15.610
10Y	-15.370	-6.315	-9.055

Measures how much money you pay for each share for every $1 in earnings Cytokinetics generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Cytokinetics to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Cytokinetics is -15.94. This means the investor is paying $-15.94 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.66.
What is the trend?
The trend is important because it shows you how Cytokinetics is performing over time. The most recent quarter might be important if Cytokinetics released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Cytokinetics up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Cytokinetics

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 99,067 = EPS
PE ratio MRQ = -15.94

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cytokinetics Inc:

The EOD is -22.858. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -29.451. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -12.975. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-22.858	MRQ	-29.451	+6.593
MRQ	-29.451	TTM	-12.975	-16.477
TTM	-12.975	YOY	-17.938	+4.964
TTM	-12.975	5Y	-10.459	-2.516
5Y	-10.459	10Y	-11.469	+1.010

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-22.858	-2.974	-19.884
MRQ	-29.451	-3.306	-26.145
TTM	-12.975	-3.508	-9.467
YOY	-17.938	-5.613	-12.325
5Y	-10.459	-8.378	-2.081
10Y	-11.469	-8.873	-2.596

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Cytokinetics is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of -22.60 means the investor is paying $-22.60 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cytokinetics Inc:

The EOD is -17.541. Based on the equity, the company is expensive. -2
The MRQ is -22.600. Based on the equity, the company is expensive. -2
The TTM is -13.983. Based on the equity, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-17.541	MRQ	-22.600	+5.059
MRQ	-22.600	TTM	-13.983	-8.618
TTM	-13.983	YOY	-72.886	+58.904
TTM	-13.983	5Y	-16.327	+2.344
5Y	-16.327	10Y	-2.214	-14.113

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-17.541	1.914	-19.455
MRQ	-22.600	2.116	-24.716
TTM	-13.983	2.097	-16.080
YOY	-72.886	2.881	-75.767
5Y	-16.327	3.550	-19.877
10Y	-2.214	3.936	-6.150

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cytokinetics Inc.

3.1. Institutions holding Cytokinetics Inc

Institutions are holding 112.318% of the shares of Cytokinetics Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	15.6324	0.0343	16102070	467330	2.989
2023-12-31	FMR Inc	12.6283	0.0834	13007783	1016959	8.4811
2023-12-31	Vanguard Group Inc	10.6955	0.0201	11016889	273565	2.5464
2023-12-31	Wellington Management Company LLP	6.2992	0.101	6488500	-1497856	-18.7552
2023-12-31	State Street Corporation	5.7214	0.0239	5893358	618872	11.7333
2023-12-31	T. Rowe Price Associates, Inc.	3.1496	0.0364	3244250	2232623	220.6963
2023-12-31	HHG PLC	2.4935	0.1279	2568405	75079	3.0112
2023-12-31	RTW INVESTMENTS, LLC	2.4514	3.2931	2525080	-49118	-1.9081
2023-12-31	Morgan Stanley - Brokerage Accounts	2.3315	0.0177	2401582	1349376	128.2426
2023-09-30	Partner Fund Management LP	2.3295	3.33	2399545	0	0
2023-12-31	T. Rowe Price Investment Management,Inc.	2.1644	0.121	2229485	413299	22.7564
2023-12-31	Boxer Capital LLC	2.0387	8.7387	2100000	0	0
2023-12-31	Geode Capital Management, LLC	2.0292	0.0183	2090125	111760	5.6491
2023-12-31	Goldman Sachs Group Inc	1.5833	0.0122	1630888	921438	129.8806
2023-12-31	Logos Global Management LP	1.5776	12.6641	1625000	375000	30
2023-12-31	Lord, Abbett & Co LLC	1.5609	0.4821	1607812	1006641	167.4467
2023-12-31	Polar Capital Holdings PLC	1.3757	0.7248	1417054	-1237391	-46.6158
2023-12-31	Pictet Asset Manangement SA	1.3322	0.1264	1372244	-875199	-38.942
2023-12-31	Amvescap Plc.	1.2067	0.0247	1242980	59100	4.9921
2023-09-30	Citadel Advisors Llc	1.1959	0.0078	1231824	331835	36.871
Total		79.7969	29.9879	82194874	+5593313	+6.8%

3.2. Funds holding Cytokinetics Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-02-29	Vanguard Total Stock Mkt Idx Inv	3.0023	0.0144	3092542	-7408	-0.239
2024-03-28	iShares Core S&P Mid-Cap ETF	2.9637	0.2516	3052717	0	0
2023-12-31	Vanguard Health Care Inv	2.7247	0.5048	2806530	-528000	-15.8343
2024-02-29	Vanguard Small Cap Index	2.4536	0.1299	2527354	23439	0.9361
2024-03-28	iShares Russell 2000 ETF	2.2698	0.2503	2337961	6547	0.2808
2024-02-29	Fidelity Select Health Care	1.6213	1.5241	1670000	70000	4.375
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.4083	0.1027	1450564	-728	-0.0502
2024-02-29	Vanguard Small Cap Growth Index Inv	1.3769	0.2936	1418271	21622	1.5481
2023-12-31	US Small-Cap Growth II Equity Comp	1.1528	0.3993	1187415	1187415	0
2023-12-31	T. Rowe Price New Horizons	1.1528	0.4007	1187415	1187415	0
2024-03-28	SPDR® S&P Biotech ETF	1.1282	1.079	1162077	14640	1.2759
2024-02-29	Fidelity Advisor Health Care I	1.0097	1.5096	1040000	40000	4
2024-01-31	Fidelity Small Cap Index	0.9137	0.2966	941112	15644	1.6904
2024-02-29	Polar Capital Healthcare Opports Inc	0.8987	3.9695	925695	-106047	-10.2784
2023-12-31	Janus Henderson Global Life Sciences D	0.8719	1.5237	898104	44686	5.2361
2023-12-31	Janus Henderson Global Life Sciences	0.8719	1.5308	898104	44686	5.2361
2024-01-31	Fidelity Small Cap Growth	0.8276	1.1618	852432	41872	5.1658
2024-02-29	Fidelity Advisor Growth Opps M	0.8241	0.3023	848900	-26200	-2.9939
2023-12-31	T. Rowe Price Health Sciences	0.8035	0.4697	827675	487066	142.9986
2023-12-31	Vanguard Explorer Inv	0.798	0.321	822004	-298182	-26.619
Total		29.0735	16.0354	29946872	+2218467	+7.4%

3.3. Insider Transactions

Insiders are holding 0.566% of the shares of Cytokinetics Inc.

Date	Owner	Type	Amount	Price
2024-04-09	Fady Ibraham Malik	SELL	32605	74.31
2024-03-05	Fady Ibraham Malik	SELL	32604	67.56
2024-02-14	John T Henderson	SELL	5000	76.48
2024-02-06	Fady Ibraham Malik	SELL	32605	79.3
2024-01-31	Robert I Blum	SELL	12500	79.57
2024-01-19	Robert I Blum	SELL	12500	81.42
2024-01-12	John T Henderson	SELL	5000	85.14
2024-01-04	Fady Ibraham Malik	SELL	15678	86.98
2024-01-02	Robert I Blum	SELL	12500	85.08
2023-12-27	Wendall Wierenga	SELL	10000	73.6
2023-11-15	Robert I Blum	SELL	12500	34.57
2023-11-09	Fady Ibraham Malik	SELL	2500	35.4
2023-10-30	Robert I Blum	SELL	12500	32.17
2023-10-16	Robert I Blum	SELL	12500	33.7
2023-10-12	Fady Ibraham Malik	SELL	2500	35.89
2023-10-06	Robert I Blum	SELL	12500	30
2023-09-14	Fady Ibraham Malik	SELL	2500	34.86
2023-09-13	Robert I Blum	SELL	12500	34.9
2023-08-25	Robert I Blum	SELL	12500	33.99
2023-08-21	Wendall Wierenga	SELL	6020	32.02

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cytokinetics Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.502	-0.666	+233%	-0.841	+268%	-0.197	+139%	-0.105	+121%
Book Value Per Share	-	-	-3.694	-3.316	-10%	0.248	-1589%	-0.287	-92%	0.261	-1517%
Current Ratio	-	-	6.117	7.832	-22%	9.824	-38%	9.288	-34%	7.684	-20%
Debt To Asset Ratio	-	-	1.469	1.436	+2%	0.960	+53%	1.049	+40%	0.762	+93%
Debt To Equity Ratio	-	-	-	-	0%	3.073	-100%	6.079	-100%	3.724	-100%
Dividend Per Share	-	-	-	0.008	-100%	-	0%	0.002	-100%	0.001	-100%
Eps	-	-	-1.309	-1.258	-4%	-0.930	-29%	-0.660	-50%	-0.394	-70%
Free Cash Flow Per Share	-	-	-0.709	-0.994	+40%	-0.743	+5%	-0.485	-32%	-0.293	-59%
Free Cash Flow To Equity Per Share	-	-	0.905	-0.465	+151%	0.491	+84%	0.209	+333%	0.133	+581%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	-20.007	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-75.325	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-1.295	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-3.735	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-4.432	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-14.591	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-8.221	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-29.057	-	-	-	-	-	-	-	-
Market Cap	6776524800.000	-29%	8731050240.000	4725789440.000	+85%	4454153280.000	+96%	3109149056.000	+181%	2008434368.000	+335%
Net Profit Margin	-	-	-81.876	-150.173	+83%	-56.389	-31%	-45.832	-44%	32.140	-355%
Operating Margin	-	-	-76.207	-141.854	+86%	-43.993	-42%	-40.898	-46%	29.006	-363%
Operating Ratio	-	-	77.207	142.854	-46%	44.993	+72%	41.968	+84%	-28.203	+137%
Pb Ratio	-17.541	+22%	-22.600	-13.983	-38%	-72.886	+222%	-16.327	-28%	-2.214	-90%
Pe Ratio	-12.375	+22%	-15.945	-8.883	-44%	-20.052	+26%	-21.868	+37%	-15.370	-4%
Price Per Share	64.800	-29%	83.490	45.190	+85%	42.593	+96%	29.731	+181%	19.206	+335%
Price To Free Cash Flow Ratio	-22.858	+22%	-29.451	-12.975	-56%	-17.938	-39%	-10.459	-64%	-11.469	-61%
Price To Total Gains Ratio	129.131	-29%	166.375	18.289	+810%	-242.441	+246%	-109.762	+166%	-15.706	+109%
Quick Ratio	-	-	10.891	14.011	-22%	17.949	-39%	16.303	-33%	13.144	-17%
Return On Assets	-	-	-0.166	-0.163	-2%	-0.112	-32%	-0.121	-27%	-0.094	-44%
Return On Equity	-	-	-	-	0%	-0.282	0%	-0.755	0%	-0.474	0%
Total Gains Per Share	-	-	0.502	-0.657	+231%	-0.841	+268%	-0.195	+139%	-0.105	+121%
Usd Book Value	-	-	-386323000.000	-346814750.000	-10%	25949500.000	-1589%	-29968800.000	-92%	27259850.000	-1517%
Usd Book Value Change Per Share	-	-	0.502	-0.666	+233%	-0.841	+268%	-0.197	+139%	-0.105	+121%
Usd Book Value Per Share	-	-	-3.694	-3.316	-10%	0.248	-1589%	-0.287	-92%	0.261	-1517%
Usd Dividend Per Share	-	-	-	0.008	-100%	-	0%	0.002	-100%	0.001	-100%
Usd Eps	-	-	-1.309	-1.258	-4%	-0.930	-29%	-0.660	-50%	-0.394	-70%
Usd Free Cash Flow	-	-	-74114000.000	-103937250.000	+40%	-77712750.000	+5%	-50681450.000	-32%	-30665225.000	-59%
Usd Free Cash Flow Per Share	-	-	-0.709	-0.994	+40%	-0.743	+5%	-0.485	-32%	-0.293	-59%
Usd Free Cash Flow To Equity Per Share	-	-	0.905	-0.465	+151%	0.491	+84%	0.209	+333%	0.133	+581%
Usd Market Cap	6776524800.000	-29%	8731050240.000	4725789440.000	+85%	4454153280.000	+96%	3109149056.000	+181%	2008434368.000	+335%
Usd Price Per Share	64.800	-29%	83.490	45.190	+85%	42.593	+96%	29.731	+181%	19.206	+335%
Usd Profit	-	-	-136896000.000	-131099000.000	-4%	-109359750.000	-20%	-71306550.000	-48%	-42434475.000	-69%
Usd Revenue	-	-	1672000.000	1882500.000	-11%	23647000.000	-93%	12762100.000	-87%	12052925.000	-86%
Usd Total Gains Per Share	-	-	0.502	-0.657	+231%	-0.841	+268%	-0.195	+139%	-0.105	+121%
	EOD	+1 -7	MRQ	TTM	+19 -14	YOY	+15 -17	5Y	+13 -21	10Y	+14 -20

4.2. Fundamental Score

Let's check the fundamental score of Cytokinetics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-12.375
Price to Book Ratio (EOD)	Between	0-1	-17.541
Net Profit Margin (MRQ)	Greater than	0	-81.876
Operating Margin (MRQ)	Greater than	0	-76.207
Quick Ratio (MRQ)	Greater than	1	10.891
Current Ratio (MRQ)	Greater than	1	6.117
Debt to Asset Ratio (MRQ)	Less than	1	1.469
Debt to Equity Ratio (MRQ)	Less than	1	0.000
Return on Equity (MRQ)	Greater than	0.15	0.000
Return on Assets (MRQ)	Greater than	0.05	-0.166
Total			3/10 (30.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Cytokinetics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	38.602
Ma 20	Greater than	Ma 50	69.911
Ma 50	Greater than	Ma 100	70.300
Ma 100	Greater than	Ma 200	69.231
Open	Greater than	Close	64.810
Total			3/5 (60.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	824,316
Total Liabilities	1,210,639
Total Stockholder Equity	-386,323

	As reported
Total Liabilities	1,210,639
Total Stockholder Equity	+ -386,323
Total Assets	= 824,316

Assets

Total Assets	824,316
Total Current Assets	628,051
Long-term Assets	196,265

Total Current Assets

Total Current Assets (as reported)	628,051
Cash And Cash Equivalents	113,399
Short-term Investments	501,800
Net Receivables	1,283
Other Current Assets	11,569
Total Current Assets (calculated)	628,051
+/-	0

Long-term Assets

Long-term Assets (as reported)	196,265
Property Plant Equipment	147,735
Long Term Investments	40,534
Long-term Assets Other	7,996
Long-term Assets (calculated)	196,265
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	102,678
Long-term Liabilities	1,107,961
Total Stockholder Equity	-386,323

Total Current Liabilities

Total Current Liabilities (as reported)	102,678
Short-term Debt	27,971
Short Long Term Debt	10,080
Accounts payable	21,507
Other Current Liabilities	53,200
Total Current Liabilities (calculated)	112,758
+/-	10,080

Long-term Liabilities

Long-term Liabilities (as reported)	1,107,961
Long term Debt	607,373
Capital Lease Obligations Min Short Term Debt	110,347
Long-term Liabilities Other	380,161
Long-term Liabilities (calculated)	1,097,881
+/-	10,080

Total Stockholder Equity

Total Stockholder Equity (as reported)	-386,323
Common Stock	102
Retained Earnings	-2,112,238
Accumulated Other Comprehensive Income	-10
Other Stockholders Equity	1,725,823
Total Stockholder Equity (calculated)	-386,323
+/-	0

Other

Capital Stock	102
Cash and Short Term Investments	615,199
Common Stock Shares Outstanding	99,067
Liabilities and Stockholders Equity	824,316
Net Debt	642,372
Net Invested Capital	231,130
Net Working Capital	525,373
Property Plant and Equipment Gross	176,083
Short Long Term Debt Total	755,771

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

> Total Assets

56,168
0
0
0
62,873
56,169
149,503
138,926
128,101
117,832
105,202
95,901
91,461
114,668
109,578
104,649
169,516
186,995
172,812
168,702
155,370
138,338
119,366
100,043
87,454
92,922
144,069
134,164
122,599
111,893
94,616
82,918
77,992
65,662
72,157
61,778
52,773
46,531
94,081
85,345
77,551
64,690
94,555
88,006
83,188
107,277
96,143
87,185
132,968
122,214
112,706
102,196
115,237
113,218
106,161
158,170
170,142
265,374
340,630
326,313
294,810
279,926
247,239
230,279
211,178
198,611
198,218
187,393
289,814
256,582
232,495
474,112
533,803
577,062
564,302
827,539
841,319
856,253
771,717
1,075,961
1,014,775
889,815
779,899
740,614
824,316

824,316

740,614

779,899

889,815

1,014,775

1,075,961

771,717

856,253

841,319

827,539

564,302

577,062

533,803

474,112

232,495

256,582

289,814

187,393

198,218

198,611

211,178

230,279

247,239

279,926

294,810

326,313

340,630

265,374

170,142

158,170

106,161

113,218

115,237

102,196

112,706

122,214

132,968

87,185

96,143

107,277

83,188

88,006

94,555

64,690

77,551

85,345

94,081

46,531

52,773

61,778

72,157

65,662

77,992

82,918

94,616

111,893

122,599

134,164

144,069

92,922

87,454

100,043

119,366

138,338

155,370

168,702

172,812

186,995

169,516

104,649

109,578

114,668

91,461

95,901

105,202

117,832

128,101

138,926

149,503

56,169

62,873

56,168

> Total Current Assets

0
0
0
0
37,076
31,131
122,777
113,556
109,067
104,825
92,282
83,655
78,864
103,107
97,590
91,413
153,621
171,660
158,021
155,205
122,016
107,510
89,335
72,783
58,910
65,332
137,100
128,151
116,921
107,089
90,139
79,258
73,498
62,954
69,804
59,871
51,140
45,221
92,960
78,769
76,427
63,665
93,620
83,321
79,338
86,054
80,078
81,491
131,131
110,810
107,900
100,515
113,107
106,118
96,618
148,184
158,633
211,023
316,996
321,987
274,295
272,339
244,229
227,269
207,674
186,400
184,951
176,535
233,752
225,938
218,954
418,412
474,221
433,117
364,229
494,941
535,672
623,526
602,250
884,275
795,186
680,629
586,575
561,416
628,051

628,051

561,416

586,575

680,629

795,186

884,275

602,250

623,526

535,672

494,941

364,229

433,117

474,221

418,412

218,954

225,938

233,752

176,535

184,951

186,400

207,674

227,269

244,229

272,339

274,295

321,987

316,996

211,023

158,633

148,184

96,618

106,118

113,107

100,515

107,900

110,810

131,131

81,491

80,078

86,054

79,338

83,321

93,620

63,665

76,427

78,769

92,960

45,221

51,140

59,871

69,804

62,954

73,498

79,258

90,139

107,089

116,921

128,151

137,100

65,332

58,910

72,783

89,335

107,510

122,016

155,205

158,021

171,660

153,621

91,413

97,590

103,107

78,864

83,655

92,282

104,825

109,067

113,556

122,777

31,131

37,076

Cash And Cash Equivalents

16,388
0
0
0
10,991
8,916
17,650
19,775
13,061
14,816
10,910
11,803
13,515
73,111
49,766
48,214
39,387
104,048
111,223
108,491
116,564
105,540
86,861
70,636
41,819
48,489
85,032
23,715
25,561
20,715
18,365
30,439
17,514
15,452
23,769
18,591
18,833
17,815
63,654
15,390
14,907
13,160
17,057
19,258
20,158
13,256
12,355
12,907
20,215
22,546
24,839
25,962
65,076
42,269
27,724
30,300
66,874
49,364
100,711
116,320
125,206
115,011
46,955
27,624
42,256
39,409
34,361
39,634
36,433
49,776
61,134
200,812
82,985
44,594
37,154
90,562
112,666
115,422
93,631
106,238
65,582
101,616
68,639
99,692
113,399

113,399

99,692

68,639

101,616

65,582

106,238

93,631

115,422

112,666

90,562

37,154

44,594

82,985

200,812

61,134

49,776

36,433

39,634

34,361

39,409

42,256

27,624

46,955

115,011

125,206

116,320

100,711

49,364

66,874

30,300

27,724

42,269

65,076

25,962

24,839

22,546

20,215

12,907

12,355

13,256

20,158

19,258

17,057

13,160

14,907

15,390

63,654

17,815

18,833

18,591

23,769

15,452

17,514

30,439

18,365

20,715

25,561

23,715

85,032

48,489

41,819

70,636

86,861

105,540

116,564

108,491

111,223

104,048

39,387

48,214

49,766

73,111

13,515

11,803

10,910

14,816

13,061

19,775

17,650

8,916

10,991

16,388

Short-term Investments

10,425
0
0
0
24,197
18,941
102,269
91,327
92,637
86,809
78,191
68,761
62,697
28,150
45,155
40,478
70,155
65,499
44,250
44,450
3,175
3,175
0
0
15,048
15,607
49,666
97,873
86,808
84,741
69,214
46,780
54,125
44,449
43,143
38,994
30,190
25,265
26,821
60,220
59,093
48,438
58,596
62,384
57,570
69,090
65,395
65,589
63,013
85,322
80,344
72,023
46,366
61,153
62,614
48,309
89,375
157,192
211,340
191,247
143,685
136,443
184,986
182,686
156,475
137,213
138,507
126,405
188,679
170,930
151,929
209,452
381,075
380,983
313,147
387,074
358,972
493,552
492,395
761,426
716,995
562,346
497,083
439,547
501,800

501,800

439,547

497,083

562,346

716,995

761,426

492,395

493,552

358,972

387,074

313,147

380,983

381,075

209,452

151,929

170,930

188,679

126,405

138,507

137,213

156,475

182,686

184,986

136,443

143,685

191,247

211,340

157,192

89,375

48,309

62,614

61,153

46,366

72,023

80,344

85,322

63,013

65,589

65,395

69,090

57,570

62,384

58,596

48,438

59,093

60,220

26,821

25,265

30,190

38,994

43,143

44,449

54,125

46,780

69,214

84,741

86,808

97,873

49,666

15,607

15,048

3,175

44,450

44,250

65,499

70,155

40,478

45,155

28,150

62,697

68,761

78,191

86,809

92,637

91,327

102,269

18,941

24,197

10,425

Net Receivables

0
0
0
0
263
204
198
182
766
781
609
1,323
727
201
231
223
42,231
359
192
257
214
235
137
146
261
47
562
4,553
189
20
211
262
46
34
27
116
14
83
3
0
4
328
16,000
0
5
2,116
319
1,191
46,646
970
4
47
12
12
26
67,000
24
910
0
10,000
1,112
18,587
10,611
15,032
6,785
6,637
9,568
6,576
5,163
2,704
2,254
4,965
4,420
4,514
2,701
644
51,819
6,056
1,973
2,294
147
1,006
985
2,499
1,283

1,283

2,499

985

1,006

147

2,294

1,973

6,056

51,819

644

2,701

4,514

4,420

4,965

2,254

2,704

5,163

6,576

9,568

6,637

6,785

15,032

10,611

18,587

1,112

10,000

910

67,000

970

46,646

1,191

319

2,116

16,000

328

116

262

211

189

4,553

562

261

146

137

235

214

257

192

359

42,231

223

231

201

727

1,323

609

781

766

182

198

204

263

Inventory

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,005
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-18,587
-10,611
-15,032
-6,785
0
-9,568
-6,576
0
0
-2,254
-4,965
-4,420
0
0
-644
-51,819
-6,056
-1,973
0
-147
-1,006
-985
-2,499
0

-2,499

-985

-1,006

-147

-1,973

-6,056

-51,819

-644

-4,420

-4,965

-2,254

-6,576

-9,568

-6,785

-15,032

-10,611

-18,587

2,005

> Long-term Assets

0
0
0
0
25,797
25,038
26,726
25,370
19,034
13,007
12,920
12,246
12,597
11,561
11,988
13,236
15,895
15,335
14,791
13,497
33,354
30,828
30,031
27,260
28,544
27,590
6,969
6,013
5,678
4,804
4,477
3,660
4,494
2,708
2,353
1,907
1,633
1,310
1,121
6,576
1,124
1,025
935
4,685
3,850
21,223
16,065
5,694
1,837
11,404
4,806
1,681
2,130
7,100
9,543
9,986
11,509
54,351
23,634
4,326
20,515
7,587
3,010
3,010
3,504
12,211
13,267
10,858
56,062
30,644
13,541
55,700
59,582
143,945
200,073
332,598
305,647
232,727
169,467
191,686
219,589
209,186
193,324
179,198
196,265

196,265

179,198

193,324

209,186

219,589

191,686

169,467

232,727

305,647

332,598

200,073

143,945

59,582

55,700

13,541

30,644

56,062

10,858

13,267

12,211

3,504

3,010

7,587

20,515

4,326

23,634

54,351

11,509

9,986

9,543

7,100

2,130

1,681

4,806

11,404

1,837

5,694

16,065

21,223

3,850

4,685

935

1,025

1,124

6,576

1,121

1,310

1,633

1,907

2,353

2,708

4,494

3,660

4,477

4,804

5,678

6,013

6,969

27,590

28,544

27,260

30,031

30,828

33,354

13,497

14,791

15,335

15,895

13,236

11,988

11,561

12,597

12,246

12,920

13,007

19,034

25,370

26,726

25,038

25,797

Property Plant Equipment

9,742
0
0
0
8,870
8,170
7,764
7,505
7,336
6,727
6,368
5,920
6,178
5,949
5,920
7,178
9,202
8,667
8,132
7,820
7,728
7,201
6,728
5,605
5,087
4,714
4,249
3,865
3,713
3,282
2,953
2,574
2,321
2,041
1,705
1,514
1,310
1,132
994
906
997
898
809
804
1,221
1,508
1,513
1,491
1,637
1,551
1,571
1,481
1,751
1,760
1,659
2,049
3,637
3,488
3,268
3,294
3,568
3,156
2,598
2,687
3,204
3,175
2,945
3,615
13,412
14,134
13,541
14,742
22,628
102,885
119,948
134,621
146,409
148,386
150,747
155,378
163,190
160,661
158,114
155,543
147,735

147,735

155,543

158,114

160,661

163,190

155,378

150,747

148,386

146,409

134,621

119,948

102,885

22,628

14,742

13,541

14,134

13,412

3,615

2,945

3,175

3,204

2,687

2,598

3,156

3,568

3,294

3,268

3,488

3,637

2,049

1,659

1,760

1,751

1,481

1,571

1,551

1,637

1,491

1,513

1,508

1,221

804

809

898

997

906

994

1,132

1,310

1,514

1,705

2,041

2,321

2,574

2,953

3,282

3,713

3,865

4,249

4,714

5,087

5,605

6,728

7,201

7,728

7,820

8,132

8,667

9,202

7,178

5,920

5,949

6,178

5,920

6,368

6,727

7,336

7,505

7,764

8,170

8,870

9,742

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,543
0
0
0
3,754
2,502
19,515
14,352
4,003
0
9,653
3,035
0
179
5,140
7,684
7,737
7,672
50,622
20,087
583
16,518
4,015
0
0
0
0
2,254
0
42,650
16,510
0
40,958
36,954
34,664
73,672
191,295
152,050
77,083
10,668
28,544
46,708
40,406
26,871
15,468
40,534

40,534

15,468

26,871

40,406

46,708

28,544

10,668

77,083

152,050

191,295

73,672

34,664

36,954

40,958

16,510

42,650

2,254

4,015

16,518

583

20,087

50,622

7,672

7,737

7,684

5,140

179

3,035

9,653

4,003

14,352

19,515

2,502

3,754

5,543

Long-term Assets Other

0
0
0
0
16,927
9,079
7,412
17,865
11,698
6,280
6,552
6,326
6,419
5,612
6,068
6,058
6,693
6,668
6,659
5,677
5,626
4,627
4,303
3,655
3,457
2,851
2,720
474
1,965
289
291
1,086
967
667
648
393
323
178
127
127
127
127
126
127
127
200
200
200
200
200
200
200
200
200
200
200
200
241
279
449
429
416
412
323
300
9,036
8,068
7,243
8,882
8,972
7,930
7,075
9,282
6,396
6,453
6,682
7,188
7,258
8,052
7,764
9,691
8,119
8,339
8,187
7,996

7,996

8,187

8,339

8,119

9,691

7,764

8,052

7,258

7,188

6,682

6,453

6,396

9,282

7,075

7,930

8,972

8,882

7,243

8,068

9,036

300

323

412

416

429

449

279

241

200

127

126

127

178

323

393

648

667

967

1,086

291

289

1,965

474

2,720

2,851

3,457

3,655

4,303

4,627

5,626

5,677

6,659

6,668

6,693

6,058

6,068

5,612

6,419

6,326

6,552

6,280

11,698

17,865

7,412

9,079

16,927

> Total Liabilities

23,452
0
0
0
154,904
153,502
21,478
20,553
20,545
20,287
17,344
17,678
17,900
15,618
16,786
19,059
63,203
65,046
61,475
59,204
55,454
51,714
46,778
42,739
37,688
45,726
25,005
21,807
21,171
18,258
7,364
6,796
7,476
6,076
5,505
5,034
4,595
4,524
4,100
4,742
6,111
6,260
42,566
48,255
28,746
21,099
17,446
13,555
40,904
38,062
37,845
34,896
46,647
55,312
57,415
74,920
75,781
169,991
165,629
179,275
184,968
180,327
172,069
178,211
185,244
195,239
203,114
207,262
300,751
302,293
310,575
324,507
420,420
509,216
547,813
578,519
597,456
739,992
660,303
1,091,938
1,122,675
1,118,835
1,113,014
1,179,415
1,210,639

1,210,639

1,179,415

1,113,014

1,118,835

1,122,675

1,091,938

660,303

739,992

597,456

578,519

547,813

509,216

420,420

324,507

310,575

302,293

300,751

207,262

203,114

195,239

185,244

178,211

172,069

180,327

184,968

179,275

165,629

169,991

75,781

74,920

57,415

55,312

46,647

34,896

37,845

38,062

40,904

13,555

17,446

21,099

28,746

48,255

42,566

6,260

6,111

4,742

4,100

4,524

4,595

5,034

5,505

6,076

7,476

6,796

7,364

18,258

21,171

21,807

25,005

45,726

37,688

42,739

46,778

51,714

55,454

59,204

61,475

65,046

63,203

19,059

16,786

15,618

17,900

17,678

17,344

20,287

20,545

20,553

21,478

153,502

154,904

23,452

> Total Current Liabilities

9,375
0
0
0
9,457
9,231
10,468
10,789
11,039
12,097
10,476
10,764
11,264
9,685
10,650
12,405
26,392
23,850
24,388
26,238
26,448
26,294
24,952
24,467
22,877
22,062
23,248
20,469
20,186
17,534
6,875
6,487
7,324
6,042
5,505
5,034
4,592
4,467
3,989
4,589
5,750
5,819
34,046
45,011
26,704
19,792
16,917
12,986
23,855
25,385
29,112
30,143
31,649
24,683
26,272
29,334
33,258
36,796
31,059
42,357
32,444
38,546
27,288
21,492
22,194
26,277
21,959
21,517
26,023
20,741
22,696
27,573
31,199
35,930
61,766
80,868
71,860
66,847
66,843
76,496
84,617
75,220
65,617
77,723
102,678

102,678

77,723

65,617

75,220

84,617

76,496

66,843

66,847

71,860

80,868

61,766

35,930

31,199

27,573

22,696

20,741

26,023

21,517

21,959

26,277

22,194

21,492

27,288

38,546

32,444

42,357

31,059

36,796

33,258

29,334

26,272

24,683

31,649

30,143

29,112

25,385

23,855

12,986

16,917

19,792

26,704

45,011

34,046

5,819

5,750

4,589

3,989

4,467

4,592

5,034

5,505

6,042

7,324

6,487

6,875

17,534

20,186

20,469

23,248

22,062

22,877

24,467

24,952

26,294

26,448

26,238

24,388

23,850

26,392

12,405

10,650

9,685

11,264

10,764

10,476

12,097

11,039

10,789

10,468

9,231

9,457

9,375

Short-term Debt

0
0
0
0
2,008
1,992
2,108
2,151
2,387
2,421
2,448
2,608
2,726
2,763
2,990
3,317
3,691
4,039
4,117
4,171
4,050
3,542
3,029
2,460
2,025
1,925
14,084
1,725
1,616
11,326
1,268
1,028
833
690
489
310
152
152
0
0
-1,355
0
-1,801
-1,789
-3,709
-1,689
-985
-1,646
-1,361
-1,392
-1,601
-1,907
-2,238
-547
-2,846
-668
2,500
4,825
7,315
9,829
-5,253
28,045
1,703
3,778
2,607
10,711
4,538
4,577
4,616
5,030
5,075
3,943
2,785
10,920
23,440
30,461
14,863
14,490
14,303
16,056
12,829
14,263
15,701
17,236
27,971

27,971

17,236

15,701

14,263

12,829

16,056

14,303

14,490

14,863

30,461

23,440

10,920

2,785

3,943

5,075

5,030

4,616

4,577

4,538

10,711

2,607

3,778

1,703

28,045

-5,253

9,829

7,315

4,825

2,500

-668

-2,846

-547

-2,238

-1,907

-1,601

-1,392

-1,361

-1,646

-985

-1,689

-3,709

-1,789

-1,801

-1,355

152

310

489

690

833

1,028

1,268

11,326

1,616

1,725

14,084

1,925

2,025

2,460

3,029

3,542

4,050

4,171

4,117

4,039

3,691

3,317

2,990

2,763

2,726

2,608

2,448

2,421

2,387

2,151

2,108

1,992

2,008

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,500
0
0
0
14,639
0
2,500
2,500
2,500
4,825
30,159
9,829
31,777
31,954
1,703
3,778
2,607
6,212
0
0
0
0
0
0
0
5,625
11,250
16,875
0
0
0
0
958
0
0
0
10,080

10,080

958

16,875

11,250

5,625

6,212

2,607

3,778

1,703

31,954

31,777

9,829

30,159

4,825

2,500

14,639

2,500

Accounts payable

1,609
0
0
0
1,589
1,032
1,926
1,214
2,059
1,252
773
1,366
2,352
1,617
1,890
2,448
2,838
1,815
2,221
2,505
1,584
2,306
1,659
1,013
1,382
1,256
924
1,349
1,683
1,700
1,196
1,013
1,119
1,045
1,005
1,450
1,196
926
1,046
1,518
2,152
1,086
1,801
1,789
3,709
1,689
985
1,646
1,361
1,392
1,601
1,907
2,238
547
2,846
668
4,236
3,042
1,783
4,079
5,253
2,424
1,336
2,024
3,764
2,547
5,194
3,412
8,160
3,527
2,920
6,738
8,050
7,766
14,928
16,222
21,087
19,836
14,078
14,429
25,611
17,357
12,561
13,796
21,507

21,507

13,796

12,561

17,357

25,611

14,429

14,078

19,836

21,087

16,222

14,928

7,766

8,050

6,738

2,920

3,527

8,160

3,412

5,194

2,547

3,764

2,024

1,336

2,424

5,253

4,079

1,783

3,042

4,236

668

2,846

547

2,238

1,907

1,601

1,392

1,361

1,646

985

1,689

3,709

1,789

1,801

1,086

2,152

1,518

1,046

926

1,196

1,450

1,005

1,045

1,119

1,013

1,196

1,700

1,683

1,349

924

1,256

1,382

1,013

1,659

2,306

1,584

2,505

2,221

1,815

2,838

2,448

1,890

1,617

2,352

1,366

773

1,252

2,059

1,214

1,926

1,032

1,589

1,609

Other Current Liabilities

5,351
0
0
0
3,060
3,407
3,634
4,624
3,793
4,125
4,455
4,690
4,786
4,605
268
216
7,629
5,762
5,816
7,328
8,580
8,212
8,030
8,760
7,174
6,584
8,240
16,687
16,136
4,291
4,411
4,446
5,372
4,290
3,748
3,274
3,244
3,541
2,943
2,942
4,877
4,690
8,517
11,689
12,003
9,396
7,933
7,702
6,813
5,443
8,119
8,776
10,791
8,772
12,713
18,837
18,462
17,955
14,019
18,879
22,872
235
16,117
38
66
75
399
389
1,124
2,507
1,013
2,406
-66,636
-69,756
-63,602
-52,815
-51,090
-54,479
38,462
46,011
46,177
43,600
5,885
13,737
53,200

53,200

13,737

5,885

43,600

46,177

46,011

38,462

-54,479

-51,090

-52,815

-63,602

-69,756

-66,636

2,406

1,013

2,507

1,124

389

399

16,117

235

22,872

18,879

14,019

17,955

18,462

18,837

12,713

8,772

10,791

8,776

8,119

5,443

6,813

7,702

7,933

9,396

12,003

11,689

8,517

4,690

4,877

2,942

2,943

3,541

3,244

3,274

3,748

4,290

5,372

4,446

4,411

4,291

16,136

16,687

8,240

6,584

7,174

8,760

8,030

8,212

8,580

7,328

5,816

5,762

7,629

216

268

4,605

4,786

4,690

4,455

4,125

3,793

4,624

3,634

3,407

3,060

5,351

> Long-term Liabilities

0
0
0
0
145,447
144,271
11,010
9,764
9,506
8,190
6,868
6,914
6,636
5,933
6,136
6,654
36,811
41,196
37,087
32,966
29,006
25,420
21,826
18,272
14,811
23,664
1,757
1,338
985
724
489
309
152
34
0
0
3
57
111
153
361
441
8,520
3,244
2,042
1,307
529
569
17,049
12,677
8,733
4,753
14,998
30,629
31,143
45,586
42,523
133,195
134,570
136,918
152,524
141,781
144,781
156,719
163,050
168,962
181,155
185,745
274,728
281,552
287,879
296,934
389,221
473,286
486,047
497,651
525,596
673,145
593,460
1,015,442
1,038,058
1,043,615
1,047,397
1,101,692
1,107,961

1,107,961

1,101,692

1,047,397

1,043,615

1,038,058

1,015,442

593,460

673,145

525,596

497,651

486,047

473,286

389,221

296,934

287,879

281,552

274,728

185,745

181,155

168,962

163,050

156,719

144,781

141,781

152,524

136,918

134,570

133,195

42,523

45,586

31,143

30,629

14,998

4,753

8,733

12,677

17,049

569

529

1,307

2,042

3,244

8,520

441

361

153

111

152

309

489

724

985

1,338

1,757

23,664

14,811

18,272

21,826

25,420

29,006

32,966

37,087

41,196

36,811

6,654

6,136

5,933

6,636

6,914

6,868

8,190

9,506

9,764

11,010

144,271

145,447

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,639
29,466
29,604
29,742
27,381
25,195
22,844
20,471
31,777
31,954
30,662
38,127
39,806
36,382
44,473
44,762
45,052
45,340
45,631
45,920
46,209
40,874
35,538
30,203
47,367
61,165
62,344
63,544
63,810
64,110
0
0
0

64,110

63,810

63,544

62,344

61,165

47,367

30,203

35,538

40,874

46,209

45,920

45,631

45,340

45,052

44,762

44,473

36,382

39,806

38,127

30,662

31,954

31,777

20,471

22,844

25,195

27,381

29,742

29,604

29,466

14,639

Capital Lease Obligations Min Short Term Debt

0
0
0
0
-2,008
-1,992
-2,108
-2,151
-2,387
-2,421
-2,448
-2,608
-2,726
-2,763
-2,990
-3,317
-3,691
-4,039
-4,117
-4,171
-4,050
-3,542
-3,029
-2,460
-2,025
-1,925
-14,084
-1,725
-1,616
-11,326
-1,268
-1,028
-833
-690
-489
-310
-152
-152
0
0
1,355
0
1,801
1,789
3,709
1,689
985
1,646
1,361
1,392
1,601
1,907
2,238
547
2,846
668
-2,500
-4,825
-7,315
-9,829
5,253
-28,045
-1,703
-3,778
-2,607
-940
4,294
3,257
2,195
1,774
591
2,517
440
80,008
88,121
94,913
112,229
112,023
112,732
114,405
126,895
125,341
123,829
122,216
110,347

110,347

122,216

123,829

125,341

126,895

114,405

112,732

112,023

112,229

94,913

88,121

80,008

440

2,517

591

1,774

2,195

3,257

4,294

-940

-2,607

-3,778

-1,703

-28,045

5,253

-9,829

-7,315

-4,825

-2,500

668

2,846

547

2,238

1,907

1,601

1,392

1,361

1,646

985

1,689

3,709

1,789

1,801

1,355

-152

-310

-489

-690

-833

-1,028

-1,268

-11,326

-1,616

-1,725

-14,084

-1,925

-2,025

-2,460

-3,029

-3,542

-4,050

-4,171

-4,117

-4,039

-3,691

-3,317

-2,990

-2,763

-2,726

-2,608

-2,448

-2,421

-2,387

-2,151

-2,108

-1,992

-2,008

Long-term Liabilities Other

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
92,928
96,659
100,575
105,747
109,827
114,118
118,591
123,244
132,580
136,682
140,983
229,676
236,212
242,248
251,014
256,012
345,412
171,790
380,448
391,229
524,980
531,116
951,898
974,248
979,505
313,788
370,457
380,161

380,161

370,457

313,788

979,505

974,248

951,898

531,116

524,980

391,229

380,448

171,790

345,412

256,012

251,014

242,248

236,212

229,676

140,983

136,682

132,580

123,244

118,591

114,118

109,827

105,747

100,575

96,659

92,928

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,520
3,244
2,042
1,307
529
569
17,049
12,677
8,733
4,753
359
1,163
1,539
15,844
15,142
15,072
15,067
15,872
15,000
0
0
0
0
0
0
0
0
0
0
0
87,000
87,000
87,000
87,000
87,000
87,000
0
0
0
0
0
0
0

87,000

15,000

15,872

15,067

15,072

15,142

15,844

1,539

1,163

359

4,753

8,733

12,677

17,049

569

529

1,307

2,042

3,244

8,520

> Total Stockholder Equity

32,716
0
0
0
-92,031
-97,333
128,025
118,373
107,556
97,545
87,858
78,223
73,561
99,050
92,792
85,590
106,313
121,949
111,337
109,498
99,916
86,624
72,588
57,304
49,766
47,196
119,064
112,357
101,428
93,635
87,252
76,122
70,516
59,586
66,652
56,744
48,178
42,007
89,981
80,603
71,440
58,430
51,989
39,751
54,442
86,178
78,697
73,630
92,064
84,152
74,861
67,300
68,590
57,906
48,746
83,250
94,361
95,383
175,001
147,038
109,842
99,599
75,170
52,068
25,934
3,372
-4,896
-19,869
-10,937
-45,711
-78,080
149,605
113,383
67,846
16,489
249,020
243,863
116,261
111,414
-15,977
-107,900
-229,020
-333,115
-438,801
-386,323

-386,323

-438,801

-333,115

-229,020

-107,900

-15,977

111,414

116,261

243,863

249,020

16,489

67,846

113,383

149,605

-78,080

-45,711

-10,937

-19,869

-4,896

3,372

25,934

52,068

75,170

99,599

109,842

147,038

175,001

95,383

94,361

83,250

48,746

57,906

68,590

67,300

74,861

84,152

92,064

73,630

78,697

86,178

54,442

39,751

51,989

58,430

71,440

80,603

89,981

42,007

48,178

56,744

66,652

59,586

70,516

76,122

87,252

93,635

101,428

112,357

119,064

47,196

49,766

57,304

72,588

86,624

99,916

109,498

111,337

121,949

106,313

85,590

92,792

99,050

73,561

78,223

87,858

97,545

107,556

118,373

128,025

-97,333

-92,031

32,716

Common Stock

2
0
0
0
2
3
28
28
28
29
29
29
30
36
37
38
43
47
47
49
49
49
49
49
50
54
61
61
61
62
64
65
67
67
72
72
75
78
133
142
143
147
29
29
31
36
37
37
39
39
39
39
40
40
40
41
41
43
53
54
54
54
55
55
768,758
55
58
59
59
59
60
70
70
71
72
84
84
85
85
93
94
94
94
94
102

102

768,758

147

143

142

133

Retained Earnings Total Equity

-1,717,283

-1,585,994

-1,448,614

-1,306,304

-1,286,484

-1,207,620

-1,177,050

-1,100,964

-1,039,400

-992,306

-948,376

-945,201

-904,421

-865,016

-834,376

-804,803

-772,690

-743,324

-714,403

-688,222

-658,349

-646,081

-605,596

-573,239

-544,158

-518,291

-525,448

-558,810

-547,199

-534,744

-525,515

-516,666

-506,115

-497,243

-505,686

-499,715

-491,340

-482,597

-489,128

-476,540

-461,499

-448,880

-437,424

-427,380

-418,438

-408,510

-396,632

-385,994

Accumulated Other Comprehensive Income

0
0
0
0
-3,605
-4,926
-5,338
-4,820
-4,439
-3,733
-3,281
-2,829
-2,466
-2,073
-1,808
-1,432
-1,169
-840
-687
-489
-330
-1,135
-1,400
-1,857
18
4
-3
24
1
-7
3
7
-4
9
15
8
3
-2
-1
13
18
10
-1
19
7
12
12
24
-4
-6
12
16
149
156
229
252
137
-9
-86
426
343
489
450
447
500
606
761
719
679
1,613
1,337
958
149
50
-22
-65
-869
-3,589
-4,494
-5,559
-3,590
-1,645
-1,458
-874
-10

-10

-874

-1,458

-1,645

-3,590

-5,559

-4,494

-3,589

-869

-65

-22

149

958

1,337

1,613

679

719

761

606

500

447

450

489

343

426

-86

-9

137

252

229

156

149

-6

-4

-1

-2

-4

-7

-3

-1,857

-1,400

-1,135

-330

-489

-687

-840

-1,169

-1,432

-1,808

-2,073

-2,466

-2,829

-3,281

-3,733

-4,439

-4,820

-5,338

-4,926

-3,605

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
452,559
453,296
456,610
460,369
517,229
517,872
518,804
519,772
528,501
528,831
537,001
577,470
578,363
579,255
589,272
590,234
591,476
592,760
603,145
604,909
607,287
609,880
612,474
639,507
748,273
752,154
755,526
757,405
762,887
765,970
768,703
775,401
799,088
813,729
853,341
857,038
865,724
1,096,953
1,105,470
1,107,135
1,117,403
1,426,051
1,452,268
1,406,249
1,422,127
1,438,103
1,481,590
1,489,814
0
0
0

1,489,814

1,481,590

1,438,103

1,422,127

1,406,249

1,452,268

1,426,051

1,117,403

1,107,135

1,105,470

1,096,953

865,724

857,038

853,341

813,729

799,088

775,401

768,703

765,970

762,887

757,405

755,526

752,154

748,273

639,507

612,474

609,880

607,287

604,909

603,145

592,760

591,476

590,234

589,272

579,255

578,363

577,470

537,001

528,831

528,501

519,772

518,804

517,872

517,229

460,369

456,610

453,296

452,559

Treasury Stock

Other Stockholders Equity

0
0
0
0
5,646
-48,573
93,069
242,617
243,239
243,051
243,452
243,466
249,521
287,074
294,336
301,677
338,078
365,073
366,936
376,218
379,730
381,137
382,730
384,163
385,605
393,730
409,639
411,106
412,729
417,132
423,881
425,087
431,103
431,872
452,559
453,296
456,610
460,369
517,229
517,872
518,804
519,772
528,501
528,831
537,001
577,470
578,363
579,255
589,272
590,234
591,476
592,760
603,145
604,909
607,287
609,880
612,474
639,507
748,273
752,154
755,526
757,405
762,887
765,970
768,703
775,401
799,088
813,729
853,341
857,038
865,724
1,096,953
1,105,470
1,107,135
1,117,403
1,426,051
1,452,268
1,406,249
1,422,127
1,438,103
1,481,590
1,489,814
1,514,169
1,537,321
1,725,823

1,725,823

1,537,321

1,514,169

1,489,814

1,481,590

1,438,103

1,422,127

1,406,249

1,452,268

1,426,051

1,117,403

1,107,135

1,105,470

1,096,953

865,724

857,038

853,341

813,729

799,088

775,401

768,703

765,970

762,887

757,405

755,526

752,154

748,273

639,507

612,474

609,880

607,287

604,909

603,145

592,760

591,476

590,234

589,272

579,255

578,363

577,470

537,001

528,831

528,501

519,772

518,804

517,872

517,229

460,369

456,610

453,296

452,559

431,872

431,103

425,087

423,881

417,132

412,729

411,106

409,639

393,730

385,605

384,163

382,730

381,137

379,730

376,218

366,936

365,073

338,078

301,677

294,336

287,074

249,521

243,466

243,452

243,051

243,239

242,617

93,069

-48,573

5,646

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31
Accounts Payable	21,507	25,611	21,087	8,050	8,160	3,764	5,253	4,236	2,238	1,361	3,709	2,152	1,196	1,119	1,683	1,382	1,584	2,838	2,352	2,059	1,589	1,609	-	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Accumulated Other Comprehensive Income	-10	-3,590	-869	149	679	500	343	137	149	-4	7	18	3	-4	1	18	-330	-1,169	-2,466	-4,439	-3,605	-10	-	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Lease Obligations	138,318	139,724	127,092	3,225	6,811	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Stock	102	94	84	70	59	55	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Capital Surpluse	0	1,481,590	1,452,268	1,105,470	853,341	768,703	755,526	612,474	603,145	589,272	537,001	0	456,610	0	0	0	0	0	0	0	0	0	-	-
Cash	113,399	65,582	112,666	82,985	36,433	42,256	125,206	66,874	65,076	20,215	20,158	14,907	18,833	17,514	25,561	41,819	116,564	39,387	13,515	13,061	10,991	16,388	-	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Cash And Short Term Investments	615,199	782,577	471,638	464,060	225,112	198,731	268,891	156,249	111,442	83,228	77,728	74,000	49,023	71,639	114,727	56,867	119,739	109,542	76,212	105,698	35,188	26,813	-	-
Common Stock	102	94	84	70	59	768,758	54	41	40	39	31	143	75	67	61	50	49	43	30	28	2	2	-	-
Common Stock Shares Outstanding	96,524	89,825	76,886	64,524	57,575	54,420	49,404	42,561	38,814	35,709	27,275	18,107	11,800	10,694	9,660	8,232	7,932	6,103	4,764	3,297	319	290	237	161
Common Stock Total Equity	0	94	84	70	59	55	54	41	40	39	31	143	75	67	61	50	49	43	30	28	2	2	-	-
Current Deferred Revenue	0	0	34,370	19,315	12,123	15,757	9,572	8,060	20,858	17,042	14,701	76	0	0	751	12,296	12,234	12,234	1,400	2,800	2,800	3,110	-	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Deferred Long Term Liab	0	0	87,000	87,000	0	0	15,000	15,142	359	17,049	2,042	0	0	0	0	0	0	0	0	0	0	0	-	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Intangible Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Inventory	0	-147	-51,819	-4,420	0	-6,785	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Liabilities And Stockholders Equity	824,316	1,014,775	841,319	533,803	289,814	211,178	294,810	170,142	115,237	132,968	83,188	77,551	52,773	77,992	122,599	87,454	155,370	169,516	91,461	128,101	62,873	56,168	79,019	61,038
Long Term Debt	607,373	63,810	47,367	46,209	45,052	39,806	31,777	27,381	14,639	0	0	0	0	152	985	2,615	4,639	7,144	6,636	8,106	8,075	7,077	-	-
Long Term Debt Total	0	63,810	47,367	46,209	45,052	39,806	31,777	27,381	14,639	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Long Term Investments	40,534	46,708	152,050	36,954	42,650	0	16,518	7,672	179	0	2,502	0	0	0	0	0	0	0	0	0	0	0	-	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Debt	642,372	683,760	157,264	55,953	99,635	157	-93,429	-39,493	-50,437	-20,215	-20,158	-14,907	-18,830	-17,362	-24,576	-37,179	-107,875	-28,552	-4,153	-2,568	-908	-6,896	3,525	1,079
Net Invested Capital	231,130	501,718	386,701	249,096	118,320	68,347	141,619	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Receivables	1,283	147	51,819	4,420	5,163	6,785	1,112	24	12	46,646	5	4	14	46	189	261	214	42,231	727	766	263	16	-	-
Net Tangible Assets	0	-107,900	243,863	113,383	-10,937	25,934	109,842	94,361	68,590	92,064	54,442	0	48,178	0	0	0	0	0	0	0	0	0	-	-
Net Working Capital	525,373	710,569	463,812	443,022	207,729	185,480	241,851	125,375	81,458	107,276	52,634	70,677	46,548	66,174	96,736	36,033	95,568	127,229	67,600	98,028	27,619	18,571	-	-
Non Current Assets Total	196,265	219,589	305,647	59,582	56,062	3,504	20,515	11,509	2,130	1,837	3,850	1,124	1,633	4,494	5,678	28,544	33,354	15,895	12,597	19,034	25,797	28,222	-	-
Non Current Liabilities Other	380,161	974,248	391,229	256,012	229,676	123,244	105,747	142	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Non Current Liabilities Total	1,107,961	1,038,058	525,596	389,221	274,728	163,050	152,524	42,523	14,998	17,049	2,042	361	3	152	985	14,811	29,006	36,811	6,636	9,506	145,447	107,381	116,371	82,856
Non Currrent Assets Other	7,996	9,691	7,188	9,282	8,882	300	429	200	200	200	127	127	323	967	291	3,457	5,626	6,693	6,419	7,143	16,927	18,480	-	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Assets	0	9,691	7,188	46,236	0	300	429	200	200	200	127	127	323	967	1,965	3,432	5,601	6,693	6,419	7,143	9,070	14,832	79,019	61,038
Other Current Assets	11,569	12,609	64,034	10,161	3,477	8,943	4,292	2,360	1,653	1,257	1,605	2,423	2,103	1,813	2,005	1,782	2,063	1,848	1,925	2,603	1,625	1,117	-	-
Other Current Liab	53,200	46,177	1,540	1,049	1,124	66	22,872	18,462	10,791	6,813	12,003	4,877	3,244	5,372	16,135	7,174	8,580	7,629	4,786	3,793	3,060	2,241	-	-
Other Liab	0	300,544	270,529	253,068	143,276	122,473	120,747	15,142	359	17,049	2,042	361	3	0	0	12,196	24,367	29,666	0	1,400	4,200	7,000	-	-
Other Stockholder Equity	1,725,823	1,481,590	1,452,268	1,105,470	853,341	768,703	755,526	612,474	603,145	589,272	537,001	518,804	456,610	431,103	412,729	385,605	379,730	338,078	158,060	115,138	5,646	809	957	617
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	133,172	93,304	-	-
Property Plant And Equipment Gross	176,083	163,190	146,409	22,628	13,412	3,204	3,568	3,637	1,751	1,637	1,221	997	1,310	2,321	3,713	5,087	7,728	9,202	6,178	7,336	8,870	9,742	-	-
Property Plant And Equipment Net	147,735	163,190	146,409	22,628	13,412	3,204	3,568	3,637	1,751	1,637	1,221	997	1,310	2,321	3,713	5,087	7,728	9,202	6,178	7,336	8,870	9,742	-	-
Property Plant Equipment	0	80,453	73,271	13,346	4,530	3,204	3,568	3,637	1,751	1,637	1,221	997	1,310	2,321	3,713	5,087	7,728	9,202	6,178	7,336	8,870	9,742	-	-
Retained Earnings	-2,112,238	-1,585,994	-1,207,620	-992,306	-865,016	-743,324	-646,081	-518,291	-534,744	-497,243	-482,597	-448,880	-408,510	-360,650	-311,363	-335,907	-279,533	-230,639	-173,524	-131,272	-94,074	-61,389	-38,309	-22,435
Retained Earnings Total Equity	0	-1,585,994	-1,207,620	-992,306	-865,016	-743,324	-646,081	-518,291	-534,744	-497,243	-482,597	0	-408,510	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt	10,080	958	0	0	0	2,607	20,192	2,500	7,641	2,500	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Short Long Term Debt Total	755,771	749,342	269,930	138,938	136,068	42,413	31,777	27,381	14,639	0	0	0	3	152	985	4,640	8,689	10,835	9,362	10,493	10,083	9,492	3,525	1,079
Short Term Debt	27,971	12,829	14,863	2,785	4,616	2,607	-5,253	2,500	-2,238	-1,361	-3,709	-1,355	152	833	1,616	2,025	4,050	3,691	2,726	2,387	2,008	2,415	-	-
Short Term Investments	501,800	716,995	358,972	381,075	188,679	156,475	143,685	89,375	46,366	63,013	57,570	59,093	30,190	54,125	89,166	15,048	3,175	70,155	62,697	92,637	24,197	10,425	-	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Assets	824,316	1,014,775	841,319	533,803	289,814	211,178	294,810	170,142	115,237	132,968	83,188	77,551	52,773	77,992	122,599	87,454	155,370	169,516	91,461	128,101	62,873	56,168	79,019	61,038
Total Current Assets	628,051	795,186	535,672	474,221	233,752	207,674	274,295	158,633	113,107	131,131	79,338	76,427	51,140	73,498	116,921	58,910	122,016	153,621	78,864	109,067	37,076	27,946	-	-
Total Current Liabilities	102,678	84,617	71,860	31,199	26,023	22,194	32,444	33,258	31,649	23,855	26,704	5,750	4,592	7,324	20,185	22,877	26,448	26,392	11,264	11,039	9,457	9,375	-	-
Total Liab	1,210,639	1,122,675	597,456	420,420	300,751	185,244	184,968	75,781	46,647	40,904	28,746	6,111	4,595	7,476	21,170	37,688	55,454	63,203	17,900	20,545	154,904	116,756	116,371	82,856
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Stockholder Equity	-386,323	-107,900	243,863	113,383	-10,937	25,934	109,842	94,361	68,590	92,064	54,442	71,440	48,178	70,516	101,429	49,766	99,916	106,313	73,561	107,556	-92,031	-60,588	-37,352	-21,818
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31
Accounts Payable	21,507	13,796	12,561	17,357	25,611	14,429	14,078	19,836	21,087	16,222	14,928	7,766	8,050	6,738	2,920	3,527	8,160	3,412	5,194	2,547	3,764	2,024	1,336	2,424	5,253	4,079	1,783	3,042	4,236	668	2,846	547	2,238	1,907	1,601	1,392	1,361	1,646	985	1,689	3,709	1,789	1,801	1,086	2,152	1,518	1,046	926	1,196	1,450	1,005	1,045	1,119	1,013	1,196	1,700	1,683	1,349	924	1,256	1,382	1,013	1,659	2,306	1,584	2,505	2,221	1,815	2,838	2,448	1,890	1,617	2,352	1,366	773	1,252	2,059	1,214	1,926	1,032	1,589	-	-	-	1,609
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Accumulated Other Comprehensive Income	-10	-874	-1,458	-1,645	-3,590	-5,559	-4,494	-3,589	-869	-65	-22	50	149	958	1,337	1,613	679	719	761	606	500	447	450	489	343	426	-86	-9	137	252	229	156	149	16	12	-6	-4	24	12	12	7	19	-1	10	18	13	-1	-2	3	8	15	9	-4	7	3	-7	1	24	-3	4	18	-1,857	-1,400	-1,135	-330	-489	-687	-840	-1,169	-1,432	-1,808	-2,073	-2,466	-2,829	-3,281	-3,733	-4,439	-4,820	-5,338	-4,926	-3,605	-	-	-	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Capital Lease Obligations	138,318	139,452	139,530	139,604	139,724	130,461	127,035	126,513	127,092	125,374	111,561	90,928	3,225	6,460	5,666	6,804	6,811	7,834	8,832	9,771	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Capital Stock	102	94	94	94	94	93	85	85	84	84	72	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Capital Surpluse	0	0	0	1,489,814	1,481,590	1,438,103	1,422,127	1,406,249	1,452,268	1,426,051	1,117,403	1,107,135	1,105,470	1,096,953	865,724	857,038	853,341	813,729	799,088	775,401	768,703	765,970	762,887	757,405	755,526	752,154	748,273	639,507	612,474	609,880	607,287	604,909	603,145	592,760	591,476	590,234	589,272	579,255	578,363	577,470	537,001	528,831	528,501	519,772	518,804	517,872	517,229	460,369	456,610	453,296	452,559	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Cash	113,399	99,692	68,639	101,616	65,582	106,238	93,631	115,422	112,666	90,562	37,154	44,594	82,985	200,812	61,134	49,776	36,433	39,634	34,361	39,409	42,256	27,624	46,955	115,011	125,206	116,320	100,711	49,364	66,874	30,300	27,724	42,269	65,076	25,962	24,839	22,546	20,215	12,907	12,355	13,256	20,158	19,258	17,057	13,160	14,907	15,390	63,654	17,815	18,833	18,591	23,769	15,452	17,514	30,439	18,365	20,715	25,561	23,715	85,032	48,489	41,819	70,636	86,861	105,540	116,564	108,491	111,223	104,048	39,387	48,214	49,766	73,111	13,515	11,803	10,910	14,816	13,061	19,775	17,650	8,916	10,991	-	-	-	16,388
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Cash And Short Term Investments	615,199	539,239	565,722	663,962	782,577	867,664	586,026	608,974	471,638	477,636	350,301	425,577	464,060	410,264	213,063	220,706	225,112	166,039	172,868	176,622	198,731	210,310	231,941	251,454	268,891	307,567	312,051	206,556	156,249	78,609	90,338	103,422	111,442	97,985	105,183	107,868	83,228	78,496	77,750	82,346	77,728	81,642	75,653	61,598	74,000	75,610	90,475	43,080	49,023	57,585	66,912	59,901	71,639	77,219	87,579	105,456	112,369	121,588	134,698	64,096	56,867	70,636	86,861	105,540	119,739	152,941	155,473	169,547	109,542	88,692	94,921	101,261	76,212	80,564	89,101	101,625	105,698	111,102	119,919	27,857	35,188	-	-	-	0
Common Stock	102	94	94	94	94	93	85	85	84	84	72	71	70	70	60	59	59	59	58	55	768,758	55	55	54	54	54	53	43	41	41	40	40	40	39	39	39	39	37	37	36	31	29	29	147	143	142	133	78	75	72	72	67	67	65	64	62	61	61	61	54	50	49	49	49	49	49	47	47	43	38	37	36	30	29	29	29	28	28	28	3	2	-	-	-	2
Common Stock Shares Outstanding	99,067	96,071	95,755	95,164	94,681	93,758	85,731	84,996	84,087	80,329	71,754	71,195	70,833	68,279	59,605	59,270	59,270	58,640	57,648	54,821	54,689	54,626	54,293	54,062	53,929	53,719	48,218	41,578	43,696	43,217	39,666	39,592	39,098	38,752	38,725	38,675	36,786	36,609	36,443	32,985	31,190	29,395	25,773	24,010	23,740	22,360	13,538	12,680	12,680	12,047	11,859	11,152	11,152	10,739	10,636	10,333	10,333	10,084	9,484	8,597	8,597	8,236	8,228	8,216	8,216	7,910	7,815	7,794	7,794	6,122	6,063	5,708	5,708	4,765	4,752	4,730	4,730	4,692	3,365	386	319	319	314	309	0
Common Stock Total Equity	0	0	0	94	94	93	85	85	84	84	72	71	70	70	60	59	59	59	58	55	55	55	55	54	54	54	53	43	41	41	40	40	40	39	39	39	39	37	37	36	31	29	29	147	143	142	133	78	75	72	72	67	67	65	64	62	61	61	61	54	50	49	49	49	49	49	47	47	43	38	37	36	30	29	29	29	28	28	28	3	2	-	-	-	0
Current Deferred Revenue	0	32,954	31,470	0	0	0	0	87,000	87,000	87,000	87,000	87,000	87,000	14,486	13,688	9,677	12,123	13,139	11,828	12,944	15,757	15,652	8,132	7,842	9,572	9,570	7,942	10,974	8,060	10,497	13,559	15,911	20,858	21,367	20,993	19,942	17,042	5,284	8,984	10,396	14,701	33,322	25,529	43	76	129	0	0	0	0	263	17	0	0	0	217	751	708	0	12,297	12,296	12,234	12,234	12,234	12,234	12,234	12,234	12,234	12,234	6,424	5,502	700	1,400	2,100	2,800	4,299	2,800	2,800	2,800	2,800	2,800	-	-	-	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Deferred Long Term Liab	0	0	0	0	0	0	0	87,000	87,000	87,000	87,000	87,000	87,000	0	0	0	0	0	0	0	0	0	0	0	15,000	15,872	15,067	15,072	15,142	15,844	1,539	1,163	359	4,753	8,733	12,677	17,049	569	529	1,307	2,042	3,244	8,520	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Inventory	0	-2,499	-985	-1,006	-147	0	-1,973	-6,056	-51,819	-644	0	0	-4,420	-4,965	-2,254	0	0	-6,576	-9,568	0	-6,785	-15,032	-10,611	-18,587	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,005	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Liabilities And Stockholders Equity	824,316	740,614	779,899	889,815	1,014,775	1,075,961	771,717	856,253	841,319	827,539	564,302	577,062	533,803	474,112	232,495	256,582	289,814	187,393	198,218	198,611	211,178	230,279	247,239	279,926	294,810	326,313	340,630	265,374	170,142	158,170	106,161	113,218	115,237	102,196	112,706	122,214	132,968	87,185	96,143	107,277	83,188	88,006	94,555	64,690	77,551	85,345	94,081	46,531	52,773	61,778	72,157	65,662	77,992	82,918	94,616	111,893	122,599	134,164	144,069	92,922	87,454	100,043	119,366	138,338	155,370	168,702	172,812	186,995	169,516	104,649	109,578	114,668	91,461	95,901	105,202	117,832	128,101	138,926	149,503	56,169	62,873	-	-	-	0
Long Term Debt	607,373	609,019	609,780	64,110	63,810	63,544	62,344	61,165	47,367	30,203	127,886	40,874	46,209	45,920	45,631	45,340	45,052	44,762	44,473	36,382	39,806	38,127	30,662	31,954	31,777	20,471	22,844	25,195	27,381	29,742	29,604	29,466	14,639	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	34	152	309	489	724	985	1,338	1,757	14,542	2,615	3,081	3,576	4,112	4,639	5,541	6,604	7,654	7,144	6,654	6,136	5,933	6,636	6,914	6,868	7,490	8,106	7,664	8,210	7,599	8,075	-	-	-	7,077
Long Term Debt Total	0	0	0	64,110	63,810	63,544	62,344	61,165	47,367	30,203	35,538	40,874	46,209	45,920	45,631	45,340	45,052	44,762	44,473	36,382	39,806	38,127	30,662	31,954	31,777	20,471	22,844	25,195	27,381	29,742	29,604	29,466	14,639	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Long Term Investments	40,534	15,468	26,871	40,406	46,708	28,544	10,668	77,083	152,050	191,295	73,672	34,664	36,954	40,958	0	16,510	42,650	0	2,254	0	0	0	0	4,015	16,518	583	20,087	50,622	7,672	7,737	7,684	5,140	179	0	3,035	9,653	0	4,003	14,352	19,515	2,502	3,754	0	0	0	5,543	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Net Debt	642,372	648,779	680,671	648,611	683,760	632,753	230,422	206,767	157,264	175,775	213,543	183,722	55,953	-60,330	76,906	87,823	99,635	12,962	18,944	12,956	157	14,281	-14,590	-83,057	-93,429	-95,849	-77,867	-24,169	-39,493	-558	1,880	-12,803	-50,437	-25,962	-24,839	-22,546	-20,215	-12,907	-12,355	-13,256	-20,158	-19,258	-17,057	-13,160	-14,907	-15,390	-63,654	-17,815	-18,681	-18,281	-23,280	-15,418	-16,529	-30,130	-17,876	-19,991	-22,960	-22,377	-69,191	-32,022	-37,179	-65,095	-80,256	-97,886	-107,875	-98,779	-100,502	-92,355	-28,552	-38,243	-40,640	-64,415	-4,153	-2,281	-1,594	-4,905	-2,568	-9,960	-7,332	675	-908	-	-	-	0
Net Invested Capital	231,130	170,218	276,665	381,603	501,718	592,553	308,432	311,937	386,701	389,983	155,625	205,234	249,096	283,627	54,294	85,084	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Net Receivables	1,283	2,499	985	1,006	147	2,294	1,973	6,056	51,819	644	2,701	4,514	4,420	4,965	2,254	2,704	5,163	6,576	9,568	6,637	6,785	15,032	10,611	18,587	1,112	10,000	0	910	24	67,000	26	12	12	47	4	970	46,646	1,191	319	2,116	5	0	16,000	328	4	0	3	83	14	116	27	34	46	262	211	20	189	4,553	562	47	261	146	137	235	214	257	192	359	42,231	223	231	201	727	1,323	609	781	766	182	198	204	263	-	-	-	0
Net Tangible Assets	0	0	-333,115	-229,020	-107,900	-15,977	111,414	116,261	243,863	249,020	16,489	67,846	113,383	149,605	-78,080	-45,711	-10,937	-19,869	-4,896	3,372	25,934	52,069	75,170	99,599	109,842	147,038	175,001	95,383	94,361	84,725	48,746	57,906	68,590	67,300	74,861	84,152	92,064	73,630	78,697	86,178	54,442	39,751	51,989	58,430	70,085	80,603	89,981	42,007	48,178	56,744	66,652	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Net Working Capital	525,373	483,693	520,958	605,409	710,569	807,779	535,407	556,679	463,812	414,073	302,463	397,187	443,022	390,839	196,258	205,197	207,729	155,018	162,992	160,123	185,480	205,777	216,941	233,793	241,851	279,630	285,937	174,227	125,375	118,850	70,346	81,435	81,458	70,372	78,788	85,425	107,276	68,505	63,161	66,262	52,634	38,310	59,574	57,846	70,677	74,180	88,971	40,754	46,548	54,837	64,299	56,912	66,174	72,771	83,264	89,555	96,735	107,682	113,852	43,270	36,033	48,316	64,383	81,216	95,568	128,967	133,633	147,810	127,229	79,008	86,940	93,422	67,600	72,891	81,806	92,728	98,028	102,767	112,309	21,900	27,619	-	-	-	0
Non Current Assets Total	196,265	179,198	193,324	209,186	219,589	191,686	169,467	232,727	305,647	332,598	200,073	143,945	59,582	55,700	13,541	30,644	56,062	10,858	13,267	12,211	3,504	3,010	3,010	7,587	20,515	4,326	23,634	54,351	11,509	9,986	9,543	7,100	2,130	1,681	4,806	11,404	1,837	5,694	16,065	21,223	3,850	4,685	935	1,025	1,124	6,576	1,121	1,310	1,633	1,907	2,353	2,708	4,494	3,660	4,477	4,804	5,678	6,013	6,969	27,590	28,544	27,260	30,031	30,828	33,354	13,497	14,791	15,335	15,895	13,236	11,988	11,561	12,597	12,246	12,920	13,007	19,034	25,370	26,726	25,038	25,797	-	-	-	0
Non Current Liabilities Other	380,161	370,457	313,788	979,505	974,248	951,898	531,116	524,980	391,229	380,448	171,790	345,412	256,012	251,014	242,248	236,212	229,676	140,983	136,682	132,580	123,244	118,591	114,118	109,827	105,747	100,575	96,659	92,928	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Non Current Liabilities Total	1,107,961	1,101,692	1,047,397	1,043,615	1,038,058	1,015,442	593,460	673,145	525,596	497,651	486,047	473,286	389,221	296,934	287,879	281,552	274,728	185,745	181,155	168,962	163,050	156,719	144,781	141,781	152,524	136,918	134,570	133,195	42,523	45,586	31,143	30,629	14,998	4,753	8,733	12,677	17,049	569	529	1,307	2,042	3,244	8,520	441	361	153	111	57	3	0	0	34	152	309	489	724	985	1,338	1,757	23,664	14,811	18,272	21,826	25,420	29,006	32,966	37,087	41,196	36,811	6,654	6,136	5,933	6,636	6,914	6,868	8,190	9,506	9,764	11,010	144,271	145,447	-	-	-	0
Non Currrent Assets Other	7,996	8,187	8,339	8,119	9,691	7,764	8,052	7,258	7,188	6,682	6,453	6,396	9,282	7,075	7,930	8,972	8,882	7,243	8,068	9,036	300	323	412	416	429	449	279	241	200	200	200	200	200	200	200	200	200	200	200	200	127	127	126	127	127	127	127	178	323	393	648	667	967	1,086	291	289	1,965	474	2,720	2,851	3,457	3,655	4,303	4,627	5,626	5,677	6,659	6,668	6,693	6,058	6,068	5,612	6,419	6,326	6,552	6,280	11,698	17,865	7,412	9,079	16,927	-	-	-	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Other Assets	0	0	8,339	0	9,691	7,764	8,052	7,258	7,188	6,682	6,453	6,396	46,236	48,033	0	0	0	7,243	8,068	9,036	300	323	412	416	16,947	1,032	20,366	50,863	7,872	7,937	7,884	5,340	379	200	3,235	9,853	200	4,203	14,552	19,715	2,629	3,881	126	127	127	5,670	127	178	323	393	648	667	2,173	1,086	1,524	1,522	1,965	2,148	2,720	22,876	23,457	21,655	23,303	23,627	25,626	5,677	6,659	6,668	6,693	6,058	6,068	5,612	6,419	6,326	6,552	6,280	11,698	17,865	18,962	16,868	16,927	-	-	-	18,480
Other Current Assets	11,569	22,177	20,853	16,667	12,609	14,317	16,224	14,552	64,034	17,305	11,227	3,026	10,161	8,148	5,891	2,528	3,477	10,496	12,083	3,141	8,943	16,959	12,288	20,885	4,292	4,420	4,945	3,557	2,360	2,575	6,254	2,696	1,653	2,483	2,713	1,972	1,257	1,804	2,009	1,592	1,605	1,679	1,967	1,739	2,423	3,159	2,482	2,058	2,103	2,170	2,865	3,019	1,813	1,777	2,349	1,613	2,358	2,010	1,840	1,189	1,782	2,001	2,337	1,735	2,063	2,007	2,356	1,754	1,848	2,498	2,438	1,645	1,925	1,768	2,572	2,419	2,603	2,272	2,660	3,070	1,625	-	-	-	1,117
Other Current Liab	53,200	13,737	5,885	43,600	46,177	46,011	38,462	-54,479	-51,090	-52,815	-63,602	-69,756	-66,636	2,406	1,013	2,507	1,124	389	399	75	66	38	16,117	235	22,872	18,879	14,019	17,955	18,462	18,837	12,713	8,772	10,791	8,776	8,119	5,443	6,813	7,702	7,933	9,396	12,003	11,689	8,517	4,690	4,877	2,942	2,943	3,541	3,244	3,274	3,748	4,290	5,372	4,446	4,411	4,291	16,136	16,687	8,240	6,584	7,174	8,760	8,030	8,212	8,580	7,328	5,816	5,762	7,629	216	268	4,605	4,786	4,690	4,455	4,125	3,793	4,624	3,634	3,407	3,060	-	-	-	5,351
Other Liab	0	0	313,163	0	300,544	291,260	283,710	365,446	270,529	261,775	258,790	255,890	253,068	160,395	154,914	148,983	143,276	137,726	132,388	127,308	123,244	118,591	114,118	109,827	16,097	15,872	15,069	15,072	15,142	15,844	1,539	1,163	359	4,753	8,733	12,677	17,049	569	529	1,307	2,042	3,244	8,520	441	361	153	111	57	3	0	0	0	0	0	0	0	0	0	0	9,122	12,196	15,191	18,250	21,308	24,367	27,425	30,483	33,542	29,666	0	0	0	0	0	0	700	1,400	2,100	2,800	3,500	4,200	-	-	-	7,000
Other Stockholder Equity	1,725,823	1,537,321	1,514,169	1,489,814	1,481,590	1,438,103	1,422,127	1,406,249	1,452,268	1,426,051	1,117,403	1,107,135	1,105,470	1,096,953	865,724	857,038	853,341	813,729	799,088	775,401	768,703	765,970	762,887	757,405	755,526	752,154	748,273	639,507	612,474	609,880	607,287	604,909	603,145	592,760	591,476	590,234	589,272	579,255	578,363	577,470	537,001	528,831	528,501	519,772	518,804	517,872	517,229	460,369	456,610	453,296	452,559	431,872	431,103	425,087	423,881	417,132	412,729	411,106	409,639	393,730	385,605	384,163	382,730	381,137	379,730	376,218	366,936	365,073	338,078	301,677	294,336	287,074	249,521	243,466	243,452	243,051	243,239	242,617	93,069	-48,573	5,646	-	-	-	0
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	133,172	133,172	-	-	-	93,304
Property Plant And Equipment Gross	176,083	155,543	158,114	160,661	163,190	155,378	0	0	0	0	119,948	102,885	22,628	14,742	13,541	14,134	13,412	3,615	2,945	3,175	3,204	2,687	2,598	3,156	3,568	3,294	3,268	3,488	3,637	2,049	1,659	1,760	1,751	1,481	1,571	1,551	1,637	1,491	1,513	1,508	1,221	804	809	898	997	906	994	1,132	1,310	1,514	1,705	2,041	2,321	2,574	2,953	3,282	3,713	3,865	4,249	4,714	5,087	5,605	6,728	7,201	7,728	7,820	8,132	8,667	9,202	7,178	5,920	5,949	6,178	5,920	6,368	6,727	7,336	7,505	7,764	8,170	8,870	-	-	-	0
Property Plant And Equipment Net	147,735	155,543	158,114	160,661	163,190	155,378	150,747	148,386	146,409	134,621	119,948	102,885	22,628	14,742	13,541	14,134	13,412	3,615	2,945	3,175	3,204	2,687	2,598	3,156	3,568	3,294	3,268	3,488	3,637	2,049	1,659	1,760	1,751	1,481	1,571	1,551	1,637	1,491	1,513	1,508	1,221	804	809	898	997	906	994	1,132	1,310	1,514	1,705	2,041	2,321	2,574	2,953	3,282	3,713	3,865	4,249	4,714	5,087	5,605	6,728	7,201	7,728	7,820	8,132	8,667	9,202	7,178	5,920	5,949	6,178	5,920	6,368	6,727	7,336	7,505	7,764	8,170	8,870	-	-	-	0
Property Plant Equipment	0	0	158,114	78,859	80,453	80,302	78,586	75,740	73,271	53,896	119,948	23,198	13,346	7,667	5,611	5,162	4,530	3,615	2,945	3,175	3,204	2,687	2,598	3,156	3,568	3,294	3,268	3,488	3,637	2,049	1,659	1,760	1,751	1,481	1,571	1,551	1,637	1,491	1,513	1,508	1,221	804	809	898	997	906	994	1,132	1,310	1,514	1,705	2,041	2,321	2,574	2,953	3,282	3,713	3,865	4,249	4,714	5,087	5,605	6,728	7,201	7,728	7,820	8,132	8,667	9,202	7,178	5,920	5,949	6,178	5,920	6,368	6,727	7,336	7,505	7,764	8,170	8,870	-	-	-	9,742
Retained Earnings	-2,112,238	-1,975,342	-1,845,920	-1,717,283	-1,585,994	-1,448,614	-1,306,304	-1,286,484	-1,207,620	-1,177,050	-1,100,964	-1,039,410	-992,306	-948,376	-945,201	-904,421	-865,016	-834,376	-804,803	-772,690	-743,324	-714,404	-688,222	-658,349	-646,081	-605,596	-573,239	-544,158	-518,291	-526,923	-558,810	-547,199	-534,744	-525,515	-516,666	-506,115	-497,243	-505,686	-499,715	-491,340	-482,597	-489,128	-476,540	-461,499	-448,880	-437,424	-427,380	-418,438	-408,510	-396,632	-385,994	-372,362	-360,650	-349,037	-336,696	-323,552	-311,363	-298,834	-290,633	-346,592	-335,907	-325,051	-308,791	-293,427	-279,533	-266,280	-254,959	-242,331	-230,639	-214,693	-199,773	-185,987	-173,524	-162,443	-152,342	-141,802	-131,272	-119,452	-109,237	-100,006	-94,074	-	-	-	0
Retained Earnings Total Equity	0	0	0	-1,717,283	-1,585,994	-1,448,614	-1,306,304	-1,286,484	-1,207,620	-1,177,050	-1,100,964	-1,039,400	-992,306	-948,376	-945,201	-904,421	-865,016	-834,376	-804,803	-772,690	-743,324	-714,403	-688,222	-658,349	-646,081	-605,596	-573,239	-544,158	-518,291	-525,448	-558,810	-547,199	-534,744	-525,515	-516,666	-506,115	-497,243	-505,686	-499,715	-491,340	-482,597	-489,128	-476,540	-461,499	-448,880	-437,424	-427,380	-418,438	-408,510	-396,632	-385,994	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Short Long Term Debt	10,080	0	0	0	958	0	0	0	0	16,875	11,250	5,625	0	0	0	0	0	0	0	6,212	2,607	3,778	1,703	31,954	31,777	9,829	30,159	4,825	2,500	2,500	2,500	0	14,639	0	0	0	2,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Short Long Term Debt Total	755,771	748,471	749,310	750,227	749,342	738,991	324,053	322,189	269,930	266,337	250,697	228,316	138,938	140,482	138,040	137,599	136,068	52,596	53,305	52,365	42,413	41,905	32,365	31,954	31,777	20,471	22,844	25,195	27,381	29,742	29,604	29,466	14,639	0	0	0	0	0	0	0	0	0	0	0	0	0	0	152	152	310	489	34	985	309	489	724	2,601	1,338	15,841	16,467	4,640	5,541	6,605	7,654	8,689	9,712	10,721	11,693	10,835	9,971	9,126	8,696	9,362	9,522	9,316	9,911	10,493	9,815	10,318	9,591	10,083	-	-	-	0
Short Term Debt	27,971	17,236	15,701	14,263	12,829	16,056	14,303	14,490	14,863	30,461	23,440	10,920	2,785	3,943	5,075	5,030	4,616	4,577	4,538	10,711	2,607	3,778	1,703	28,045	-5,253	9,829	7,315	4,825	2,500	-668	-2,846	-547	-2,238	-1,907	-1,601	-1,392	-1,361	-1,646	-985	-1,689	-3,709	-1,789	-1,801	0	-1,355	0	0	152	152	310	489	690	833	1,028	1,268	11,326	1,616	1,725	14,084	1,925	2,025	2,460	3,029	3,542	4,050	4,171	4,117	4,039	3,691	3,317	2,990	2,763	2,726	2,608	2,448	2,421	2,387	2,151	2,108	1,992	2,008	-	-	-	0
Short Term Investments	501,800	439,547	497,083	562,346	716,995	761,426	492,395	493,552	358,972	387,074	313,147	380,983	381,075	209,452	151,929	170,930	188,679	126,405	138,507	137,213	156,475	182,686	184,986	136,443	143,685	191,247	211,340	157,192	89,375	48,309	62,614	61,153	46,366	72,023	80,344	85,322	63,013	65,589	65,395	69,090	57,570	62,384	58,596	48,438	59,093	60,220	26,821	25,265	30,190	38,994	43,143	44,449	54,125	46,780	69,214	84,741	86,808	97,873	49,666	15,607	15,048	0	0	3,175	3,175	44,450	44,250	65,499	70,155	40,478	45,155	28,150	62,697	68,761	78,191	86,809	92,637	91,327	102,269	18,941	24,197	-	-	-	10,425
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Total Assets	824,316	740,614	779,899	889,815	1,014,775	1,075,961	771,717	856,253	841,319	827,539	564,302	577,062	533,803	474,112	232,495	256,582	289,814	187,393	198,218	198,611	211,178	230,279	247,239	279,926	294,810	326,313	340,630	265,374	170,142	158,170	106,161	113,218	115,237	102,196	112,706	122,214	132,968	87,185	96,143	107,277	83,188	88,006	94,555	64,690	77,551	85,345	94,081	46,531	52,773	61,778	72,157	65,662	77,992	82,918	94,616	111,893	122,599	134,164	144,069	92,922	87,454	100,043	119,366	138,338	155,370	168,702	172,812	186,995	169,516	104,649	109,578	114,668	91,461	95,901	105,202	117,832	128,101	138,926	149,503	56,169	62,873	-	-	-	56,168
Total Current Assets	628,051	561,416	586,575	680,629	795,186	884,275	602,250	623,526	535,672	494,941	364,229	433,117	474,221	418,412	218,954	225,938	233,752	176,535	184,951	186,400	207,674	227,269	244,229	272,339	274,295	321,987	316,996	211,023	158,633	148,184	96,618	106,118	113,107	100,515	107,900	110,810	131,131	81,491	80,078	86,054	79,338	83,321	93,620	63,665	76,427	78,769	92,960	45,221	51,140	59,871	69,804	62,954	73,498	79,258	90,139	107,089	116,921	128,151	137,100	65,332	58,910	72,783	89,335	107,510	122,016	155,205	158,021	171,660	153,621	91,413	97,590	103,107	78,864	83,655	92,282	104,825	109,067	113,556	122,777	31,131	37,076	-	-	-	0
Total Current Liabilities	102,678	77,723	65,617	75,220	84,617	76,496	66,843	66,847	71,860	80,868	61,766	35,930	31,199	27,573	22,696	20,741	26,023	21,517	21,959	26,277	22,194	21,492	27,288	38,546	32,444	42,357	31,059	36,796	33,258	29,334	26,272	24,683	31,649	30,143	29,112	25,385	23,855	12,986	16,917	19,792	26,704	45,011	34,046	5,819	5,750	4,589	3,989	4,467	4,592	5,034	5,505	6,042	7,324	6,487	6,875	17,534	20,186	20,469	23,248	22,062	22,877	24,467	24,952	26,294	26,448	26,238	24,388	23,850	26,392	12,405	10,650	9,685	11,264	10,764	10,476	12,097	11,039	10,789	10,468	9,231	9,457	-	-	-	9,375
Total Liab	1,210,639	1,179,415	1,113,014	1,118,835	1,122,675	1,091,938	660,303	739,992	597,456	578,519	547,813	509,216	420,420	324,507	310,575	302,293	300,751	207,262	203,114	195,239	185,244	178,211	172,069	180,327	184,968	179,275	165,629	169,991	75,781	74,920	57,415	55,312	46,647	34,896	37,845	38,062	40,904	13,555	17,446	21,099	28,746	48,255	42,566	6,260	6,111	4,742	4,100	4,524	4,595	5,034	5,505	6,076	7,476	6,796	7,364	18,258	21,171	21,807	25,005	45,726	37,688	42,739	46,778	51,714	55,454	59,204	61,475	65,046	63,203	19,059	16,786	15,618	17,900	17,678	17,344	20,287	20,545	20,553	21,478	153,502	154,904	-	-	-	23,452
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Total Stockholder Equity	-386,323	-438,801	-333,115	-229,020	-107,900	-15,977	111,414	116,261	243,863	249,020	16,489	67,846	113,383	149,605	-78,080	-45,711	-10,937	-19,869	-4,896	3,372	25,934	52,068	75,170	99,599	109,842	147,038	175,001	95,383	94,361	83,250	48,746	57,906	68,590	67,300	74,861	84,152	92,064	73,630	78,697	86,178	54,442	39,751	51,989	58,430	71,440	80,603	89,981	42,007	48,178	56,744	66,652	59,586	70,516	76,122	87,252	93,635	101,428	112,357	119,064	47,196	49,766	57,304	72,588	86,624	99,916	109,498	111,337	121,949	106,313	85,590	92,792	99,050	73,561	78,223	87,858	97,545	107,556	118,373	128,025	-97,333	-92,031	-	-	-	32,716
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31
Begin Period Cash Flow	65,582	112,666	82,985	36,433	42,256	125,206	66,874	65,076	20,215	20,158	14,907	18,833	17,514	25,561	41,819	116,564	39,387	13,515	13,061	10,278	16,388	11,244
Capital Expenditures	1,416	11,335	48,872	11,052	2,619	889	2,877	1,596	562	1,104	542	125	443	493	550	658	2,563	5,370	1,465	1,400	3,051	6,570
Cash And Cash Equivalents Changes	0	-45,484	29,681	46,552	-5,823	-82,950	58,332	1,798	44,861	57	5,251	-3,926	1,319	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	24,047	64,194	15,965	18,518	-1,254	12,502	-707	-396	274	818	-320	-238	0	0	0	0	0	0	0	0	0
Change In Cash	47,817	-45,484	29,681	46,552	-5,823	-82,950	58,332	1,798	44,861	57	5,251	-3,926	1,319	-8,047	-16,258	-74,745	77,177	25,872	454	2,783	-5,397	5,144
Change In Working Capital	3,089	-24,704	8,456	89,117	-336	-22,936	487	12,126	37,246	-34,011	22,048	2,616	-2,298	-1,476	-24,715	-13,630	37,279	2,184	-1,898	-2,092	-2,218	-1,904
Change Receivables	0	56,672	-47,399	743	-2,932	-1,119	-1,088	-12	46,634	-46,641	0	10	32	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-1,136	56,672	-47,399	743	-2,932	-1,119	-1,088	-12	46,634	-46,641	0	10	32	134	41	-145	-41,515	-41,515	-544	74	0	1,054
Change To Inventory	0	0	0	1,484	-5,352	4,908	-1,395	8,238	2,599	-2,591	0	-67,544	-49,040	-67,248	-1,349	-1,370	83,241	2,347	-68,763	-100,307	0	-342
Change To Liabilities	0	-75,690	19,764	94,007	2,228	-3,553	3,736	12,845	-8,992	12,356	21,230	2,926	-2,092	0	0	0	894	2,786	881	906	1,317	49
Change To Netincome	0	78,596	33,957	23,687	11,678	9,761	8,961	7,662	4,546	3,324	3,518	3,725	3,266	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	1,100	54,800	1,484	-6,354	-246	-1,395	8,238	2,599	-2,591	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	11,892	5,814	2,276	1,831	1,293	1,239	1,920	741	589	490	433	591	1,297	1,900	2,021	2,456	2,829	2,927	3,062	3,276	3,181	2,849
Dividends Paid	-18,459	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	113,399	67,182	112,666	82,985	36,433	42,256	125,206	66,874	65,076	20,215	20,158	14,907	18,833	17,514	25,561	41,819	116,564	39,387	13,515	13,061	10,991	16,388
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-415,749	-310,851	-191,394	-2,109	-93,526	-102,104	-104,636	35,386	4,321	-45,947	-8,260	-33,563	-46,038	-45,323	7,866	-61,986	-5,568	-52,540	-40,949	-35,432	-33,564	-28,873
Investments	349,913	-250,799	-98,905	-185,463	-72,088	6,008	-62,951	-50,513	16,624	-2,945	-990	-28,888	25,149	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	1,312	15,144	312,049	225,108	36,214	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	473,526	334,661	334,661	1,710	9,898	1,261	14,996	14,890	14,890	0	-152	-833	0	0	0	0	0	0	0	0	0
Net Income	-526,244	-388,955	-215,314	-127,290	-121,692	-106,289	-127,790	16,453	-37,501	-14,646	-33,717	-40,370	-47,860	-49,287	24,544	-56,374	-48,894	-57,115	-42,252	-37,198	-32,685	-23,080
Other Cashflows From Financing Activities	39,483	670,005	12,380	11,271	245,761	13,132	106,135	16,892	15,242	-22	-1,519	15,138	11,750	13,938	19,311	-4,050	-2,144	1,474	4,417	410	58	4,803
Other Cashflows From Investing Activities	0	0	0	0	-72,088	14	-62,951	33	1	-2,945	13	196	595	886	1,106	2,547	996	0	1,268	1,115	5,907	0
Other Non Cash Items	20,246	60,476	32,384	28,238	19,069	17,010	14,663	534	3	3,330	3,597	-56	-47,666	-49,278	1,700	6,217	5,768	4,842	1,604	1,982	1,209	-168
Sale Purchase Of Stock	18,459	17,543	-4,449	-2,255	37,607	3,234	126,477	1,896	9,025	48,949	0	12,318	9,329	0	0	0	-2	-2	-25	-20	0	-2
Stock Based Compensation	72,065	47,853	26,832	17,620	10,759	9,761	9,028	7,146	4,567	3,330	3,597	3,783	3,069	4,017	4,906	5,606	4,643	4,643	1,427	1,876	0	0
Total Cash From Financing Activities	221,317	516,166	319,980	234,124	159,791	13,132	225,919	16,892	23,915	48,949	14,488	58,327	21,613	2,546	28,806	-3,451	34,720	86,724	5,446	102,321	40,236	4,869
Total Cash From Operating Activities	-414,333	-299,516	-142,522	8,943	-90,907	-101,215	-101,759	36,982	4,883	-44,843	-7,718	-33,438	-45,595	-44,830	8,416	-61,328	-3,005	-47,170	-39,484	-34,032	-30,513	-22,303
Total Cashflows From Investing Activities	0	-262,134	-147,777	-196,515	-74,707	5,133	-65,828	-52,076	16,063	-4,049	-1,519	-28,815	25,301	34,237	0	0	45,462	0	34,492	0	0	22,578

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2002-12-31
Begin Period Cash Flow	100,067	69,014	103,216	67,182	106,238	93,631	115,422	112,666	90,562	37,154	44,594	82,985	200,812	61,134	49,776	36,433	39,634	34,361	39,409	42,256	27,624	46,955	115,011	125,206	116,320	100,711	49,364	66,874	30,300	27,724	42,269	65,076	25,962	24,839	22,546	20,215	12,907	12,355	13,256	20,158	19,258	17,057	13,160	14,907	15,390	63,654	17,815	18,833	18,591	23,769	15,452	17,514	30,439	18,365	20,715	25,561	23,715	85,032	48,489	41,819	70,636	86,861	105,540	116,564	108,491	111,223	104,048	39,387	48,214	49,766	73,111	13,515	11,803	10,910	14,816	13,061	19,775	17,650	8,916	10,991	0	0
Capital Expenditures	77	220	717	402	3,205	6,331	857	942	17,754	15,700	8,792	6,626	6,555	2,592	864	1,041	1,306	1,006	50	257	210	358	60	261	780	451	258	1,388	854	306	16	420	204	53	175	130	247	100	424	333	252	69	44	177	59	46	7	13	25	101	142	175	87	132	120	154	211	70	50	219	20	71	188	379	396	220	292	1,655	1,635	1,837	973	925	206	412	374	473	288	780	204	128	3,051	6,570
Cash And Cash Equivalents Changes	0	0	0	36,034	-39,056	12,607	-21,791	2,756	22,104	53,408	-7,440	-38,391	-117,827	139,678	11,358	13,343	-3,201	5,273	-5,048	-2,847	14,632	-19,331	-68,056	-10,195	8,886	15,609	51,347	-17,510	36,574	2,576	-14,545	-22,807	39,114	1,123	2,293	2,331	7,308	552	-901	-6,902	900	2,201	3,897	-1,747	-483	-48,264	45,839	-1,018	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	0	2,464	3,696	9,808	3,421	7,122	19,168	11,190	14,788	19,048	-5,664	7,016	6,037	8,576	-6,380	7,014	10,094	7,790	-17,748	2,423	11,850	2,221	4,438	4,413	2,444	1,207	215	3,678	-3,558	-1,042	830	-211	-299	-716	547	205	-418	-60	74	16,288	-16,228	684	736	-677	-424	45	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	13,332	31,053	-34,202	36,034	-39,056	12,607	-21,791	2,756	22,104	53,408	-7,440	-38,391	-117,827	139,678	11,358	13,343	-3,201	5,273	-5,048	-2,847	14,632	-19,331	-68,056	-10,195	8,886	15,609	51,347	-17,510	36,574	2,576	-14,545	-22,807	39,114	1,123	2,293	2,331	7,308	552	-901	-6,902	900	2,201	3,897	-1,747	-483	-48,264	45,839	-1,018	242	-5,178	8,317	-2,062	-12,925	12,074	-2,350	-4,846	1,846	-61,317	36,543	6,670	-28,817	-16,225	-18,679	-11,024	8,073	-2,732	7,175	64,661	-8,827	-1,552	-23,345	59,596	1,712	893	-3,906	1,755	-6,714	2,125	8,734	-2,075	0	0
Change In Working Capital	44,879	1,481	-24,099	-19,172	16,840	11,731	-93,767	40,492	-34,036	17,446	18,690	6,356	84,733	5,614	1,155	-2,385	3,678	949	-385	-4,578	7,371	-16,704	-6,599	-7,004	9,058	-81	-8,706	216	66,973	-46,193	-1,702	-6,952	-2,195	-2,764	15	42,190	-17,596	-4,561	-1,977	-9,877	-19,627	21,950	20,418	-693	3,296	-36	-755	111	-331	383	2	-2,352	1,207	387	-1,568	-1,502	4,426	-5,116	-21,227	-2,798	-3,763	-3,243	-4,508	-2,116	-2,972	-1,152	-3,077	44,480	872	1,298	251	-237	-192	223	-2,645	716	-495	136	595	-2,328	0	0
Change Receivables	0	0	0	-859	2,147	-321	4,083	50,763	-51,175	2,057	1,813	-94	545	-2,711	450	2,459	1,413	2,417	-4,828	-1,934	6,925	-8,920	-199	1,075	8,888	-10,000	909	-885	66,976	-66,974	-26	12	36	-43	965	45,676	-45,456	-871	1,797	-2,111	0	0	328	-324	-4	3	80	-69	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	1,216	-1,514	21	-859	2,147	-321	4,083	50,763	-51,175	2,057	1,813	-94	545	-2,711	450	2,459	1,413	2,417	-4,828	-1,934	6,925	-8,920	-199	1,075	8,888	-10,000	909	-885	66,976	-66,974	-26	12	36	-43	965	45,676	-45,456	-871	1,797	-2,111	-4	4	328	-324	-4	3	80	-69	102	-89	7	12	216	-49	-202	169	4,364	-4,021	-516	214	-145	8	25	41,938	41,959	41,932	42,006	41,938	-41,515	511	503	526	-544	0	0	-78	-66	81	65	74	0	1,054
Change To Inventory	0	0	0	0	0	0	0	0	0	0	0	-386,690	-2,240	3,439	270	-1,227	-3,404	-584	919	-2,283	-8,546	3,825	3,944	5,685	1,045	4,135	-5,487	-1,088	38	11,657	-2,050	-1,407	2,484	548	1,701	-2,134	-89	-699	-1,183	-620	-1,565	0	-40,212	-57,265	-66,516	-74,690	-89,926	-40,317	-46,721	-54,828	-64,296	-59,243	-65,232	-72,190	-84,088	-91,328	-218	-109,199	-134,230	54	-679	0	0	-40,506	-40,904	0	0	-844	-85,694	0	0	-93,853	-67,057	0	0	-91,421	-98,955	0	0	-23,745	0	0
Change To Liabilities	0	0	-4,323	-16,566	12,494	11,847	-91,761	-8,270	3,270	15,840	1,667	-7,167	89,784	8,009	1,911	-5,697	4,483	-462	1,890	-3,683	15,523	-3,989	-11,592	-3,495	23	9,564	-8,191	2,340	1,257	15,628	1,882	-5,922	-3,061	-2,510	-651	-2,770	27,313	-3,895	-3,356	-7,706	-19,697	5,662	36,318	-1,053	2,564	638	-411	135	0	0	0	0	0	0	0	0	0	0	789	0	0	0	0	622	894	0	0	0	2,786	2,922	1,200	0	881	601	0	0	906	1,168	701	0	1,317	49
Change To Netincome	0	0	29,076	22,116	19,195	35,528	12,195	11,678	13,836	7,767	12,825	5,261	10,944	4,692	4,527	3,524	11,678	8,020	7,541	6,751	9,761	6,218	6,658	6,805	2,455	2,447	2,219	1,840	2,000	2,007	1,925	1,730	1,328	1,120	1,202	896	886	891	853	694	579	846	1,127	966	907	1,062	854	902	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	-19,797	-19,797	1,645	8,646	-2,000	-7,191	13,282	15,811	15,210	10,497	-4,124	4,507	1,312	-211	-2,483	-261	-101	-3,509	-163	-674	-1,882	2,473	-1,395	4,135	-5,487	-1,239	8,238	3,678	-3,558	0	2,599	0	0	0	-2,591	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	6,335	1,854	1,855	1,848	1,658	1,408	1,407	1,341	734	462	543	537	471	536	416	408	391	336	280	286	-320	268	618	673	610	450	439	421	224	177	170	170	151	146	147	145	137	126	122	105	88	101	120	124	129	140	144	178	229	255	390	423	463	471	477	489	494	501	511	515	563	619	635	639	659	670	745	755	706	726	744	751	743	760	771	788	815	827	815	819	0	0
Dividends Paid	0	0	0	-3,547	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,307	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	113,399	100,067	69,014	103,216	67,182	106,238	93,631	115,422	112,666	90,562	37,154	44,594	82,985	200,812	61,134	49,776	36,433	39,634	34,361	39,409	42,256	27,624	46,955	115,011	125,206	116,320	100,711	49,364	66,874	30,300	27,724	42,269	65,076	25,962	24,839	22,546	20,215	12,907	12,355	13,256	20,158	19,258	17,057	13,160	14,907	15,390	63,654	17,815	18,833	18,591	23,769	15,452	17,514	30,439	18,365	20,715	25,561	23,715	85,032	48,489	41,819	70,636	86,861	105,540	116,564	108,491	111,223	104,048	39,387	48,214	49,766	73,111	13,515	11,803	10,910	14,816	13,061	19,775	17,650	8,916	10,991	0
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-74,114	-96,425	-122,522	-122,688	-101,395	-90,371	-91,332	-27,753	-62,491	-54,470	-38,288	-36,145	45,595	11,775	-28,303	-31,176	-20,361	-21,274	-24,727	-27,164	-12,537	-32,593	-26,906	-30,068	-24,851	-25,934	-31,519	-22,332	76,975	-12,428	-11,234	-17,927	-10,146	-10,400	-9,362	34,229	-8,377	-9,615	-9,800	-18,155	-12,681	10,240	6,580	-12,399	-7,183	-8,924	-8,706	-8,750	-10,970	-9,365	-12,648	-13,055	-9,178	-10,449	-13,334	-12,362	-6,557	-11,637	38,067	-12,007	-13,092	-16,649	-18,044	-14,201	-14,434	-10,467	-13,741	33,074	-14,807	-13,499	-12,320	-11,914	-10,297	-9,159	-12,419	-9,074	-11,369	-9,433	-7,482	-7,148	0	0
Investments	-81,411	73,039	82,128	165,899	32,454	-286,041	66,125	-63,337	65,089	-193,017	27,673	1,350	-167,063	-98,431	35,501	44,530	-103,960	14,688	-2,717	19,901	26,704	3,035	-44,128	20,397	31,543	40,109	-23,691	-110,912	-41,116	14,276	-3,932	-19,741	25,614	11,359	11,614	-31,963	6,551	10,167	8,864	-28,527	6,055	-7,523	-10,169	10,647	6,675	-38,928	-1,555	4,920	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	162,921	0	0	0	0	0	0	0	15,144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	-212	-212	-105	523,586	-267	-50,060	-47,799	-47,799	-47,799	0	0	0	0	0	133,860	133,860	1,710	1,710	1,710	9,898	9,898	9,898	1,261	1,261	1,261	1,261	14,996	0	0	14,996	14,890	0	0	0	14,890	0	0	0	0	0	0	0	0	0	0	-152	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-136,896	-129,422	-128,637	-131,289	-137,380	-142,310	-19,820	-89,445	-30,570	-76,086	-61,554	-47,104	-43,930	-3,175	-40,780	-39,405	-30,640	-29,573	-32,113	-29,366	-26,468	-22,017	-27,523	-30,281	-40,485	-32,357	-29,081	-25,867	8,632	31,887	-11,611	-12,455	-9,229	-8,849	-10,551	-8,872	8,443	-5,971	-8,374	-8,744	6,531	-12,588	-15,041	-12,619	-11,456	-10,044	-8,943	-9,928	-11,878	-10,639	-13,632	-11,712	-11,613	-12,341	-13,144	-12,189	-12,529	-8,201	55,959	-10,685	-10,856	-16,260	-15,363	-13,895	-13,252	-11,321	-12,629	-11,692	-15,946	-14,920	-13,785	-12,464	-11,081	-10,101	-10,540	-10,530	-11,820	-10,215	-9,231	-5,932	0	0
Other Cashflows From Financing Activities	-81,411	50,000	5,475	-10,517	-5,096	527,929	3,683	141,645	4,362	300,895	3,175	-3,596	39,866	1,226	4,160	-11	121,120	459	2,699	-701	451	10,227	2,978	20,136	9,754	1,442	11,680	90,819	715	727	589	14,861	14,972	-3,137	-4,492	65	32	-2,452	35	-89	5,813	-7,592	1,307	10,470	153	-3	12,321	2,819	2,497	-9,855	9,253	11,071	5,028	-20	5,560	3,370	20	-47,650	-14,054	19,291	-962	-1,003	-1,049	-1,036	-8,800	6,767	-971	858	-16,091	7,213	11,018	-666	5,387	206	-595	-581	678	-503	718	-492	0	0
Other Cashflows From Investing Activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	44,530	-72,088	31,872	17,184	19,901	14	-20,696	-23,731	20,397	0	0	0	0	0	1	32	0	1	0	0	0	0	0	0	0	10	0	3	0	196	196	53	145	592	573	349	349	886	886	441	441	1,106	1,076	518	518	2,547	2,547	1,120	1,020	996	996	8	0	0	0	72	626	1,268	1,233	944	844	1,115	0	0	0	5,907	0
Other Non Cash Items	15,388	11,166	10,407	11,133	7,194	31,956	9,510	11,816	9,580	11,641	5,732	5,431	6,572	6,700	7,243	7,723	-3,243	8,020	7,541	6,751	-2,671	6,218	6,658	6,805	4,291	4,058	3,868	2,446	139	138	138	119	1,348	1,121	1,202	896	886	0	859	694	656	845	1,130	966	28,914	-10,046	-8,955	-9,969	-11,684	-10,638	3	761	-49,287	7	9	994	83	-11	1,665	-37	981	2,306	1,380	1,550	1,518	1,556	1,512	1,183	1,205	1,234	1,443	23	439	371	369	425	419	599	543	421	0	0
Sale Purchase Of Stock	0	0	0	3,547	17,543	1,844	3,683	0	19,479	0	0	3,596	3,641	37,451	1,998	0	1,393	11,400	20,429	4,385	451	329	2,978	-524	933	1,434	106,557	17,553	715	727	589	-135	8,755	3,301	4,533	65	9,134	2,452	35	39,780	0	-478	0	0	0	-3	12,321	0	0	9,855	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	-7	-1	-1	0	0	0	-2	-1	-22	-2	-9	0	0	0	0
Stock Based Compensation	19,487	18,716	18,668	15,194	13,498	13,175	12,195	8,985	6,711	7,767	7,093	5,261	4,877	4,692	4,527	3,524	10,759	0	0	0	9,761	0	0	0	2,440	2,447	2,219	1,922	1,880	1,866	1,789	1,611	1,348	1,121	1,202	896	886	891	859	694	656	845	1,130	966	907	1,064	869	943	841	736	731	761	852	1,159	1,012	994	1,172	1,261	1,224	1,249	5,606	0	0	1,160	5,553	0	0	1,160	4,643	0	0	938	1,427	0	0	402	926	0	0	389	0	0
Total Cash From Financing Activities	168,800	54,219	5,475	-7,177	29,885	389,019	3,416	93,846	19,506	300,895	3,175	-3,596	3,641	226,334	4,160	-11	121,120	11,859	22,396	4,416	451	10,227	2,978	-524	2,194	1,434	106,557	115,734	715	727	589	14,861	23,645	164	41	65	9,134	2,452	35	39,780	7,516	-516	7,483	5	25	-412	56,047	2,667	2,394	-179	19,651	-253	4,814	-372	-4,554	2,658	-281	-2,100	12,480	18,707	-694	-1,003	-740	-1,014	1,245	6,900	-426	27,001	36,506	7,310	6,585	36,323	5,880	262	-191	-505	1,285	-478	101,786	-272	40,236	4,869
Total Cash From Operating Activities	-74,037	-96,205	-121,805	-122,286	-98,190	-84,040	-90,475	-26,811	-44,737	-38,770	-29,496	-29,519	52,150	14,367	-27,439	-30,135	-19,055	-20,268	-24,677	-26,907	-12,327	-32,235	-26,846	-29,807	-24,071	-25,483	-31,261	-20,944	77,829	-12,122	-11,218	-17,507	-9,942	-10,347	-9,187	34,359	-8,130	-9,515	-9,376	-17,822	-12,429	10,309	6,624	-12,222	-7,124	-8,878	-8,699	-8,737	-10,945	-9,264	-12,506	-12,880	-9,091	-10,317	-13,214	-12,208	-6,346	-11,567	38,117	-11,788	-13,072	-16,578	-17,856	-13,822	-14,038	-10,247	-13,449	34,729	-13,172	-11,662	-11,347	-10,989	-10,091	-8,747	-12,045	-8,601	-11,081	-8,653	-7,278	-7,020	0	0
Total Cashflows From Investing Activities	0	0	82,128	165,497	29,249	-292,372	65,268	-64,279	47,335	-208,717	18,881	-5,276	-173,618	-101,023	34,637	43,489	-105,266	13,682	-2,767	19,644	26,508	2,677	-44,188	20,136	30,763	39,658	-23,949	-112,300	-41,970	13,971	-3,916	-20,161	25,411	11,306	11,439	-32,093	6,304	10,067	8,440	-28,860	5,813	-7,592	-10,210	10,470	6,616	-38,974	-1,509	5,052	25,301	16,508	12,243	11,071	34,237	42,885	20,122	4,704	0	0	0	0	0	5,085	3,729	3,812	45,462	24,596	23,981	2,931	0	18,479	15,679	34,262	34,492	28,569	19,191	10,861	0	0	0	5,217	0	22,578

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31
Cost Of Revenue	11,892	240,813	159,938	96,951	86,125	89,135	90,296	59,897	46,398	44,426	49,450	35,000	49,475	50,312	53,445	66,570	67,280	61,538	50,483	48,600	39,986	32,528	-	-
Depreciation And Amortization	11,892	11,342	331	5,329	5,828	1,239	1,920	741	589	490	433	591	1,297	1,900	2,021	2,456	2,829	2,927	3,062	3,276	3,181	2,849	-	-
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Ebit	-496,205	-324,202	-186,313	-93,943	-98,867	-85,964	-112,714	18,687	-37,407	-14,754	-33,894	-39,749	-46,877	-49,635	24,028	-54,133	-56,487	-61,338	-44,633	-38,434	-32,590	-23,981	-18,392	-13,793
Ebitda	-484,313	-312,860	-185,982	-88,614	-93,039	-84,725	-110,794	19,428	-36,818	-14,264	-33,461	-39,158	-45,580	-47,735	26,049	-51,677	-53,658	-58,411	-41,571	-35,158	-29,409	-21,132	-18,392	-13,793
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Gross Profit	-4,362	-146,225	-89,510	-41,123	-59,257	-57,634	-76,928	46,510	-17,740	2,514	-18,802	-27,441	4,000	2,577	81,538	12,420	13,622	3,127	8,912	13,442	10,577	11,396	8,466	-
Income Before Tax	-526,244	-388,955	-215,314	-127,290	-121,692	-106,289	-127,790	16,453	-37,501	-14,646	-33,717	-39,015	-47,860	-49,463	24,694	-56,374	-48,894	-57,115	-42,252	-37,198	0	0	-	-
Income Tax Expense	0	13,597	27,056	36,845	27,360	4,191	682	-741	-589	-490	-433	-678	-209	-176	150	-232	0	0	0	0	95	-901	15,874	13,079
Interest Expense	57,668	51,156	29,332	38,676	27,360	21,564	16,996	2,234	94	108	177	87	104	163	409	491	699	523	535	549	2,490	1,331	438	267
Interest Income	25,962	11,342	331	5,329	4,535	4,191	2,602	464	94	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Net Income	-526,244	-402,552	-242,370	-164,135	-149,052	-106,289	-127,790	16,453	-37,501	-14,646	-33,717	-39,015	-47,860	-49,287	24,544	-56,374	-48,894	-57,115	-42,252	-37,198	-32,685	-23,080	-15,874	-13,079
Net Income Applicable To Common Shares	0	-388,955	-215,314	-127,290	-121,692	-106,289	-127,790	16,453	-37,501	-14,646	-33,717	-41,677	-50,717	0	24,544	0	0	0	0	0	0	0	-	-
Net Income From Continuing Ops	-526,728	-332,274	-202,422	-104,577	-100,955	-88,522	-113,810	16,453	-37,501	-14,646	-33,717	-40,370	-47,860	0	0	0	0	0	0	0	0	0	-	-
Net Interest Income	-30,911	-39,814	-29,001	-33,347	-22,825	-17,373	-14,394	-2,234	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Non Operating Income Net Other	0	11,342	331	5,329	4,535	4,191	2,602	464	-94	108	177	87	104	0	0	0	0	0	0	0	0	0	-	-
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	-56	1,192	0	0	0	0	0	0	0	0	0	-	-
Operating Income	-496,205	-324,202	-186,313	-93,943	-98,867	-88,916	-113,396	18,687	-37,407	-14,754	-33,894	-39,102	-47,964	-49,635	26,095	-59,079	-56,487	-61,338	-44,633	-38,434	-32,590	-23,981	-18,392	-13,793
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Other Operating Expenses	503,735	418,790	256,741	149,771	125,735	120,417	126,764	87,720	66,065	61,694	64,542	46,717	50,772	52,212	55,466	69,026	70,109	64,465	53,545	51,876	43,167	35,377	26,858	13,793
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	1,307	2,857	0	0	0	0	0	0	0	0	0	-	-
Reconciled Depreciation	7,215	5,814	2,276	1,831	1,293	1,239	1,920	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Research Development	318,231	6,588	159,938	96,951	86,125	89,135	90,296	59,897	46,398	44,426	49,450	35,000	37,182	38,013	39,840	53,950	53,388	49,225	40,570	39,885	34,004	28,424	20,961	10,403
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Selling General Administrative	173,612	177,977	96,803	52,820	39,610	31,282	36,468	27,823	19,667	17,268	15,092	11,717	13,590	14,199	15,626	15,076	16,721	15,240	12,975	11,991	9,163	6,953	5,897	-
Tax Provision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-
Total Operating Expenses	491,843	177,977	96,803	52,820	39,610	31,282	36,468	27,823	19,667	17,268	15,092	11,717	50,772	52,212	55,466	69,026	70,109	64,465	53,545	51,876	43,167	35,377	26,858	13,793
Total Other Income Expense Net	-30,039	-64,753	-29,001	-33,347	-22,825	-17,373	-14,394	-2,234	-94	108	177	56	-1,192	172	23	-2,473	7,593	4,223	2,381	1,236	0	0	-	-
Total Revenue	7,530	94,588	70,428	55,828	26,868	31,501	13,368	106,407	28,658	46,940	30,648	7,559	4,000	2,577	81,538	12,420	13,622	3,127	8,912	13,442	10,577	11,396	8,466	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31
Cost Of Revenue	6,335	82,532	83,194	79,421	75,018	62,734	57,126	45,935	43,498	48,436	36,443	31,561	29,221	24,202	21,790	21,738	18,334	20,229	24,017	23,545	23,278	21,391	21,582	22,135	26,250	24,947	19,809	19,289	18,775	19,340	9,723	13,534	13,249	11,557	12,636	8,956	8,779	11,420	11,737	12,490	13,824	13,445	12,347	9,834	9,214	11,648	10,666	11,623	11,233	11,839	14,311	12,092	12,268	12,489	13,140	12,415	12,929	13,234	13,818	13,464	13,748	16,726	18,476	17,620	17,409	16,661	16,996	16,214	16,429	15,380	15,592	14,137	13,097	11,823	12,671	12,892	13,701	12,277	11,606	11,016	10,905	10,475	9,520	9,086	32,528
Depreciation And Amortization	6,335	6,839	6,779	6,425	5,919	5,552	864	415	734	462	543	537	471	536	416	408	391	336	280	286	-320	268	618	673	610	450	439	421	224	177	170	170	151	146	147	145	137	126	122	105	88	101	120	124	129	140	144	178	229	255	390	423	463	471	477	489	494	501	511	515	563	619	635	639	659	670	745	755	706	726	744	751	743	760	771	788	815	827	815	819	0	-	3,040	2,123	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-127,418	-122,265	-122,049	-124,473	-127,030	-108,441	-10,874	-77,857	-22,438	-69,432	-54,610	-40,321	-34,732	5,726	-31,392	-29,639	-22,376	-23,243	-25,952	-23,377	-20,239	-16,859	-22,905	-25,962	-36,363	-28,874	-25,633	-23,672	7,464	32,313	-11,181	-12,124	-9,172	-9,034	-10,736	-9,054	8,284	-6,124	-8,529	-8,875	6,344	-12,712	-15,188	-12,771	-10,262	-10,217	-9,126	-10,200	-10,616	-10,923	-14,037	-12,175	-11,593	-13,036	-13,631	-12,772	-11,784	-8,751	59,242	-10,959	-11,178	-11,728	-16,037	-15,190	-14,958	-13,200	-14,564	-13,764	-16,980	-16,001	-14,889	-13,468	-11,696	-10,729	-11,101	-11,108	-12,290	-10,655	-9,521	-5,968	0	0	-7,772	-7,130	0
Ebitda	-121,083	-115,426	-115,270	-118,048	-121,111	-102,889	-10,010	-77,442	-21,704	-68,970	-54,067	-39,784	-34,261	6,262	-30,976	-29,231	-21,985	-22,907	-25,672	-23,091	-20,559	-16,591	-22,287	-25,289	-35,753	-28,424	-25,194	-23,251	7,688	32,490	-11,011	-11,954	-9,021	-8,888	-10,589	-8,909	8,421	-5,998	-8,407	-8,770	6,432	-12,611	-15,068	-12,647	-10,133	-10,077	-8,982	-10,022	-10,387	-10,668	-13,647	-11,752	-11,130	-12,565	-13,154	-12,283	-11,290	-8,250	59,753	-10,444	-10,615	-11,109	-15,402	-14,551	-14,299	-12,530	-13,819	-13,009	-16,274	-15,275	-14,145	-12,717	-10,953	-9,969	-10,330	-10,320	-11,475	-9,828	-8,706	-5,149	-40,523	2,644	-4,732	-5,007	0
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	-4,663	-82,154	-82,327	-74,808	-73,061	-60,219	31,842	-44,787	12,102	-42,999	-33,600	-25,013	-22,499	17,486	-18,197	-17,913	-13,122	-14,174	-16,880	-15,081	-13,901	-10,750	-15,367	-16,867	-26,268	-18,767	-16,756	-15,136	14,363	39,707	-3,921	-5,113	-3,492	-3,612	-6,094	-4,542	12,979	-2,005	-3,949	-4,511	10,525	-8,976	-11,338	-9,013	-7,030	1,714	1,841	1,820	757	1,427	1,053	763	1,099	394	462	621	1,023	5,506	71,930	3,078	3,152	3,125	3,074	3,069	3,110	4,130	3,177	3,205	155	106	1,446	1,420	2,144	1,855	2,341	2,572	2,226	2,449	2,900	5,867	2,644	2,644	2,554	2,749	0
Income Before Tax	-136,896	-129,422	-128,637	-131,289	-137,380	-142,310	-19,820	-89,445	-30,570	-76,086	-61,554	-47,104	-43,930	-3,175	-40,780	-39,405	-30,640	-29,573	-32,113	-29,366	-26,469	-22,017	-27,523	-30,281	-40,484	-32,357	-29,081	-25,867	7,157	31,887	-11,611	-12,455	-9,229	-8,849	-10,551	-8,872	8,443	-5,971	-8,374	-8,744	6,531	-12,588	-15,041	-12,619	-10,100	-10,044	-8,943	-9,928	-11,878	-10,639	-13,632	-11,712	-11,613	-12,517	-13,144	-12,189	-56,374	-8,202	55,959	-10,685	-56,374	-16,259	-15,364	-13,895	-48,894	-11,321	-12,628	-11,692	-57,115	-14,920	-13,786	0	-42,252	-10,101	-10,540	0	-37,198	0	-9,231	-5,932	0	0	0	0	0
Income Tax Expense	0	0	0	-1,848	-5,919	33,869	8,946	11,588	8,489	-231	187	290	1,675	542	966	723	1,330	684	764	1,141	1,220	1,055	508	169	163	-450	-439	-421	-224	-177	-170	-170	-151	-146	-147	-145	-137	-126	-122	-105	-88	-101	-120	-124	-129	-171	-170	-231	1,281	-255	-390	-423	176	-176	-477	-489	37,072	-528	1,642	-216	-45,518	2,039	0	0	-35,641	0	0	0	-41,170	0	0	-1,004	-31,171	0	0	-578	-25,379	-439	0	0	8,171	8,171	-37	0	0
Interest Expense	17,064	13,996	13,367	13,241	16,269	15,767	9,810	9,310	8,866	7,116	6,944	6,783	9,669	9,437	9,804	9,766	8,264	6,666	6,441	5,989	5,910	5,426	5,236	4,992	4,731	3,933	3,887	2,616	531	603	600	501	208	39	38	37	22	27	33	26	99	23	27	28	33	1	0	3	70	7	14	15	20	13	61	69	92	106	111	100	93	118	135	145	168	176	186	169	140	134	125	124	145	128	127	134	968	0	490	483	0	0	0	0	0
Interest Income	7,586	6,839	6,779	6,425	5,919	4,144	864	415	377	231	187	290	2,146	1,078	1,382	723	1,330	1,020	1,044	4,848	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-136,896	-129,422	-128,637	-129,441	-131,461	-176,179	-28,766	-101,033	-30,570	-76,086	-61,554	-47,104	-43,930	-3,175	-40,780	-39,405	-30,640	-29,573	-32,113	-29,366	-26,469	-22,017	-27,523	-30,281	-40,484	-32,357	-29,081	-25,867	7,157	31,887	-11,611	-12,455	-9,229	-8,849	-10,551	-8,872	8,443	-5,971	-8,374	-8,744	6,531	-12,588	-15,041	-12,619	-10,100	-10,044	-8,943	-9,928	-11,878	-10,639	-13,632	-11,712	-11,613	-12,341	-13,144	-12,189	-12,529	-8,202	55,959	-10,685	-10,856	-16,259	-15,364	-13,895	-13,252	-11,321	-12,628	-11,692	-15,946	-14,920	-13,786	-12,464	-11,081	-10,101	-10,540	-10,530	-11,820	-10,216	-9,231	-5,932	-8,171	-8,171	-7,735	-7,130	0
Net Income Applicable To Common Shares	0	0	-128,637	-131,289	-137,380	-142,310	-19,820	-89,445	-30,570	-76,086	-61,554	-47,104	-43,930	-3,175	-40,780	-39,405	-30,640	-29,573	-32,113	-29,366	-26,468	-22,017	-27,523	-30,281	-40,485	-32,357	-29,081	-25,867	7,157	33,362	-11,611	-12,455	-9,229	-8,849	-10,551	-8,872	8,443	-5,971	-8,374	-8,744	6,531	-12,588	-15,041	-12,619	-11,455	-10,044	-10,250	-9,928	0	-10,639	-16,489	0	0	0	0	0	24,544	-55,959	55,959	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	-136,896	-129,422	-128,637	-125,009	-125,475	-111,101	-12,817	-82,881	-26,299	-73,131	-61,554	-44,309	-45,153	9,160	-34,868	-33,716	-25,107	-24,252	-27,049	-24,547	-21,727	-17,458	-23,185	-26,152	-30,222	-32,357	-25,364	-25,867	7,157	33,362	-11,611	-12,455	-9,229	-8,849	-10,551	-8,872	8,443	-5,971	-8,374	-8,744	6,531	-12,588	-15,041	-12,619	-11,455	-10,044	-8,943	-9,928	0	-10,639	-13,632	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	-9,478	-7,157	-6,588	-6,816	-10,350	-11,623	-8,946	-8,895	-8,866	-6,885	-6,757	-6,493	-7,523	-8,359	-8,422	-9,043	-6,934	-5,646	-5,397	-4,848	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Non Operating Income Net Other	0	0	0	6,425	8,612	4,144	864	-2,278	-377	231	187	290	3,224	0	1,382	723	1,330	1,020	1,044	1,141	900	1,323	1,126	842	775	779	612	436	1,454	111	-600	-501	-208	39	38	37	22	27	33	26	99	23	27	28	33	29	13	12	0	29	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2	-13	-41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-127,418	-122,265	-122,049	-124,473	-127,030	-108,441	-10,874	-77,857	-21,704	-69,201	-54,797	-40,611	-36,407	5,184	-32,358	-30,362	-23,706	-23,927	-26,716	-24,518	-21,459	-17,914	-23,413	-26,131	-36,527	-28,424	-25,194	-23,251	7,688	32,490	-11,011	-11,954	-9,021	-8,888	-10,589	-8,909	8,421	-5,998	-8,407	-8,770	6,432	-12,611	-15,068	-12,647	-10,133	-10,073	-8,956	-9,940	-11,897	-10,668	-13,647	-11,752	-11,632	-12,565	-13,154	-12,283	-12,400	-8,208	57,545	-10,843	-11,140	-16,712	-16,037	-15,190	-14,958	-13,200	-14,564	-13,764	-16,980	-16,001	-14,889	-13,468	-11,696	-10,729	-11,101	-11,108	-12,290	-10,655	-9,521	-5,968	-40,523	2,644	-7,772	-7,130	0
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	129,090	122,643	122,916	129,086	128,987	110,956	99,842	79,005	77,304	74,638	57,640	47,159	43,129	36,504	35,951	34,187	28,918	29,982	33,853	32,982	30,836	28,555	29,628	31,399	36,509	34,604	28,247	27,404	25,450	26,557	16,813	20,375	18,778	16,833	17,131	13,323	13,337	15,413	16,195	16,749	17,917	17,080	16,077	13,468	12,317	11,789	10,810	11,801	11,462	12,095	14,700	12,515	12,731	12,959	13,616	12,904	13,423	13,735	14,329	13,979	14,311	17,345	19,111	18,259	18,068	17,330	17,741	16,969	17,135	16,107	16,335	14,888	13,840	12,584	13,442	13,680	14,516	13,104	12,421	11,835	43,167	0	7,286	7,756	0
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,307	0	0	0	2,857	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Reconciled Depreciation	6,335	1,854	1,855	1,848	1,658	1,408	1,407	1,341	734	462	543	537	471	536	416	408	391	336	280	286	-320	268	618	673	610	450	439	421	224	177	170	170	151	146	147	145	137	126	122	105	88	101	120	124	129	140	144	178	229	255	390	423	463	471	477	489	494	501	511	515	563	619	635	639	659	670	745	755	706	726	744	751	743	760	771	788	815	827	815	819	0	-	-	-	0
Research Development	78,641	378	867	2,113	6,587	2,515	1	1,148	43,498	48,436	36,443	31,561	29,221	24,202	21,790	21,738	18,334	20,229	24,017	23,545	23,278	21,391	21,582	22,135	26,250	24,947	19,809	19,289	18,775	19,340	9,723	13,534	13,249	11,557	12,636	8,956	8,779	11,420	11,737	12,490	13,824	13,445	12,347	9,834	9,214	8,798	8,242	8,745	8,599	8,891	10,513	9,179	9,161	9,547	10,236	9,068	9,822	9,857	10,202	9,959	11,470	13,519	14,859	14,102	13,958	13,217	13,726	12,486	13,026	12,535	12,397	11,266	10,735	9,259	10,039	10,537	11,241	9,535	9,749	9,360	9,863	9,099	7,286	7,756	28,424
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Selling General Administrative	44,114	40,111	39,722	49,665	53,969	48,222	42,716	33,070	33,806	26,202	21,197	15,598	13,908	12,302	14,161	12,449	10,584	9,753	9,836	9,437	7,558	7,164	8,046	9,264	10,259	9,657	8,438	8,115	6,675	7,217	7,090	6,841	5,529	5,276	4,495	4,367	4,558	3,993	4,458	4,259	4,093	3,635	3,730	3,634	3,103	2,991	2,568	3,056	2,863	3,204	4,187	3,336	3,570	3,412	3,380	3,836	3,601	3,878	4,127	4,020	2,841	3,826	4,252	4,157	4,110	4,113	4,015	4,483	4,109	3,572	3,938	3,622	3,105	3,325	3,403	3,143	3,275	3,569	2,672	2,475	0	0	0	0	0
Tax Provision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Total Operating Expenses	122,755	40,111	39,722	49,665	53,969	48,222	42,716	33,070	33,806	26,202	21,197	15,598	13,908	12,302	14,161	12,449	10,584	9,753	9,836	9,437	7,558	7,164	8,046	9,264	10,259	9,657	8,438	8,115	6,675	7,217	7,090	6,841	5,529	5,276	4,495	4,367	4,558	3,993	4,458	4,259	4,093	3,635	3,730	3,634	3,103	11,789	10,810	11,801	11,462	12,095	14,700	12,515	12,731	12,959	13,616	12,904	13,423	13,735	14,329	13,979	14,311	17,345	19,111	18,259	18,068	17,330	17,741	16,969	17,135	16,107	16,335	14,888	13,840	12,584	13,442	13,680	14,516	13,104	12,421	11,835	-43,167	0	7,286	7,756	0
Total Other Income Expense Net	-9,478	-7,157	-6,588	-6,816	-10,350	-33,869	-8,946	-11,588	-8,489	-6,885	-6,757	-6,493	-7,523	-8,359	-8,422	-9,043	-6,934	-5,646	-5,397	-4,848	-5,010	-4,103	-4,110	-4,150	-3,958	-3,933	-3,887	-2,616	-531	-603	-600	-501	-208	39	38	37	22	27	33	26	99	23	27	28	33	2	13	41	19	29	15	40	19	48	10	94	-1,585	21	-1,641	58	19	-2,492	673	1,295	-90,422	1,879	1,936	2,072	-101,473	1,081	1,103	0	-75,190	628	561	0	-63,342	0	290	36	0	0	0	0	0
Total Revenue	1,672	378	867	4,613	1,957	2,515	88,968	1,148	55,600	5,437	2,843	6,548	6,722	41,688	3,593	3,825	5,212	6,055	7,137	8,464	9,377	10,641	6,215	5,268	-18	6,180	3,053	4,153	33,138	59,047	5,802	8,421	9,757	7,945	6,542	4,414	21,758	9,415	7,788	7,979	24,349	4,469	1,009	821	2,184	1,714	1,841	1,820	757	1,427	1,053	763	1,099	394	462	621	1,023	5,506	71,930	3,078	3,152	3,125	3,074	3,069	3,110	4,130	3,177	3,205	155	106	1,446	1,420	2,144	1,855	2,341	2,572	2,226	2,449	2,900	5,867	2,644	2,644	2,554	2,749	11,396

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	7,530
Cost of Revenue	-11,892
Gross Profit	-4,362	-4,362

Operating Income (+$)
Gross Profit	-4,362
Operating Expense	-491,843
Operating Income	-496,205	-496,205

Operating Expense (+$)
Research Development	318,231
Selling General Administrative	173,612
Selling And Marketing Expenses	0
Operating Expense	491,843	491,843

Net Interest Income (+$)
Interest Income	25,962
Interest Expense	-57,668
Other Finance Cost	-795
Net Interest Income	-30,911

Pretax Income (+$)
Operating Income	-496,205
Net Interest Income	-30,911
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	-526,244	-466,166 EBIT - interestExpense = -553,873 -526,244 -468,576
Interest Expense	57,668
Earnings Before Interest and Taxes (EBIT)	-496,205	-468,576
Earnings Before Interest and Taxes (EBITDA)	-484,313

After tax Income (+$)
Income Before Tax	-526,244
Tax Provision	-0
Net Income From Continuing Ops	-526,728	-526,244
Net Income	-526,244
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	503,735
Total Other Income/Expenses Net	-30,039	30,911

Technical Analysis of Cytokinetics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cytokinetics. The general trend of Cytokinetics is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cytokinetics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (14.3%)		Bearish trend (-14.3%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Cytokinetics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 68.43 < 75.71 < 80.99.

The bearish price targets are: 61.33 > 55.80 > 54.74.

Tweet this

Cytokinetics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cytokinetics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Cytokinetics Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cytokinetics Inc. The current macd is -1.26024495.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytokinetics price going down in the near term. -2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cytokinetics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cytokinetics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1

Cytokinetics Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Cytokinetics Inc. The current adx is 21.51.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cytokinetics shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1

Cytokinetics Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cytokinetics Inc. The current sar is 72.38.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Cytokinetics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cytokinetics Inc. The current rsi is 38.60. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Cytokinetics Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cytokinetics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH < 20: The STOCH %K is below 20 and oversold. -2
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytokinetics price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

Cytokinetics Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cytokinetics Inc. The current cci is -142.590576.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1

Cytokinetics Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cytokinetics Inc. The current cmo is -32.18239543.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Cytokinetics Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Cytokinetics Inc. The current willr is -92.37933954.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1

Cytokinetics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Cytokinetics Inc.

Cytokinetics Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cytokinetics Inc. The current atr is 3.01271165.

Cytokinetics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cytokinetics Inc. The current obv is 69,829,860.

Cytokinetics Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cytokinetics Inc. The current mfi is 28.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Cytokinetics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Cytokinetics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2023-12-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-07	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-13	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-19	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-20	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-21	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-27	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-03	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-08	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-11	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-16	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-01-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-29	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-30	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-02-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-07	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-14	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-20	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-23	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-26	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-27	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-28	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-19	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-20	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-03-21	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-25	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-03-26	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-04-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-04-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-04	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-04-08	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-04-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-15	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-16	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-04-17	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-18	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-24	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-25	STOCH	LONG EXIT		The %K line crosses below the %D line.

6.3. Candlestick Patterns

Cytokinetics Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Cytokinetics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	38.602
Ma 20	Greater than	Ma 50	69.911
Ma 50	Greater than	Ma 100	70.300
Ma 100	Greater than	Ma 200	69.231
Open	Greater than	Close	64.810
Total			3/5 (60.0%)

Create your own Symbol Scanner

Get notifications about Cytokinetics Inc

I send you an email if I find something interesting about Cytokinetics Inc.

Cytokinetics Inc Buy, Hold or Sell?

Let's analyse Cytokinetics together

Get notifications about Cytokinetics Inc

Quick analysis of Cytokinetics (30 sec.)

What can you expect buying and holding a share of Cytokinetics? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Cytokinetics (5 min.)

$64.80

$-3.69

$-75.33 - $-20.01

$-79.02 - $-23.70

2. Growth of Cytokinetics (5 min.)

Is Cytokinetics growing?

How much money is Cytokinetics making?

How much money comes from the company's main activities?

3. Financial Health of Cytokinetics (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Cytokinetics? (5 min.)

What can you expect buying and holding a share of Cytokinetics?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Cytokinetics

About Cytokinetics Inc

Financial Health

Valuation

1.1. Profitability of Cytokinetics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Cytokinetics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Cytokinetics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Cytokinetics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Cytokinetics Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Cytokinetics Inc
Buy, Hold or Sell?